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Interaction of an antigen with the B cell antigen receptor (BCR) initiates signaling 
cascades leading to B cell activation, proliferation and differentiation. Signal transduction 
downstream of the BCR depends on the adaptor protein SLP65 (SH2 domain-containing 
leukocyte adaptor protein of 65 kDa). Upon BCR activation, SLP65 translocates from the 
cytosol to the plasma membrane via a poorly understood mechanism, and recruits the 
enzymes Btk (Bruton’s tyrosine kinase) and PLCγ2 (Phospholipase C-γ2), necessary for 
the release of the key secondary messenger Ca2+. As recently shown by our group, the 
pre-formed complex of SLP65 with CIN85 (Cbl-interacting protein of 85 kDa) is 
indispensable for efficient BCR signaling initiation (Oellerich et al., 2011). For my 
dissertation, I investigated the plasma membrane targeting process of this so called 
“primary BCR transducer module”. Using imaging and biochemical assays, my colleagues 
and I showed that signaling-competent SLP65 is distributed between the cytosol and 
intracellular exosome-like vesicles in resting DT40 cells. Vesicular localization of SLP65 
depended on its positively charged amino (N)-terminal region, encompassing 50 amino 
acids. I found that the N terminus of SLP65 is a direct lipid-binding module, which 
preferentially binds to negatively charged and curved membranes in vitro. In vivo, the N 
terminus of SLP65 could be functionally substituted by the curvature-sensitive lipid-
binding N-BAR domain of Amphiphysin. However, lipid binding by the N terminus or the 
BAR domain was insufficient to target SLP65 to vesicles in the absence of CIN85 binding, 
indicating that the N terminus and CIN85 cooperate for precise subcellular targeting of 
SLP65. The finding that pre-assembly of signaling adaptors on vesicles is required for B 
cell activation indicates that these signaling complexes may be delivered to the BCR via 
vesicular transport. Analysis of the secondary structure of SLP65 by Nuclear Magnetic 
Resonance (NMR) spectroscopy, in collaboration with the group of Prof. Christian 
Griesinger, showed that the N terminus of SLP65 is intrinsically disordered in solution, as 
well as upon lipid binding. Large regions of intrinsic disorder were also observed in the 
central part of SLP65. I investigated the functional role of intrinsic disorder in this region 
by substituting it with a flexible GS linker, or by rearranging the Btk- and PLCγ2- binding 
motifs. My results indicate that secondary structure in this region is dispensable for the 
assembly of the Ca2+ initiation complex, but might be required for the membrane targeting 
of SLP65 via the vesicular route. Altogether, my studies contribute to the understanding of 






The immune system has evolved to protect a host organism from pathogens. Immune 
responses can be broadly classified as innate and adaptive. Innate immune response 
occurs rapidly upon exposure to a pathogen and is mediated by protective physical and 
chemical barriers such as mucosal linings and antimicrobial proteins, which prevent the 
spread of infection; and by specialized white blood cells such as neutrophils and 
macrophages, which engulf the pathogens and destroy them. The receptors of innate 
immune cells mediating this recognition are encoded in the germline of an organism and 
have broad specificity for repetitive molecular patterns on the pathogen’s surface. 
Adaptive immune response, on the other hand, takes time to develop and is mediated by 
B and T lymphocytes, specialized immune cells, which have the ability to recognize and 
respond to individual antigens. T lymphocytes mediate the cellular immune response – 
they activate other cells of the immune system and stimulate them to produce cytokines 
that help to fight the infection. B lymphocytes mediate the humoral immune response – 
they differentiate into plasma cells and produce antibodies, which bind to pathogens and 
together with the complement system and phagocytotic cells contribute to pathogen 
elimination. Antigen receptors of the adaptive immune system are generated throughout 
the individual’s life time by the process of somatic recombination, and the receptors of B 
cells are also further diversified upon encounter with the antigen by somatic 
hypermutation. As a result of these mechanisms, each lymphocyte expresses a unique 
receptor of defined antigen specificity on its cell surface. A population of lymphocytes 
therefore expresses a vast repertoire of receptors, able to respond to virtually any kind of 
antigen (Murphy, 2011).  
The first step in B cell activation is the interaction of a B cell antigen receptor (BCR) at the 
cell surface with its cognate antigen. This activates signaling cascades inside the cell, 
which lead to proliferation and differentiation of immunocompetent B cells or apoptosis of 
autoreactive B cells. Following antigen binding, the BCR-antigen complex gets 
internalized and processed inside the endosomal compartment. The antigenic peptides 
can then be presented on the major histocompatibiliy complex (MHC) class II molecules at 
the cell surface to activated T cells of similar antigen specificity. However, the specific 
peptide recognized by helper T cell may be different from the protein epitope recognized 
by the BCR. T cells interact with the MHC molecules via their T cell antigen receptors 
(TCRs) and provide co-stimulatory signals to the B cell, necessary for full activation. The 
interaction between B and T cells takes place in the peripheral lymphoid tissues where 
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they occupy different areas, but migrate towards the same location upon activation by the 
antigen. Following activation by helper T cells, B cells may form germinal centers in the 
lymphoid organs, which are the sites of intense B cell proliferation and differentiation. 
Activated B cells may differentiate into antibody producing plasma cells or long-lived 
memory B cells, which persist in the organism’s lymphoid tissues and mediate secondary 
immune response upon reinfection with the same pathogen (Murphy, 2011). 
2.1 The B cell antigen receptor (BCR) complex 
The BCR complex consists of a membrane bound immunoglobulin molecule (mIg), acting 
as the antigen recognition component, and a non-covalently associated disulfide-linked 
Igα (CD79a) – Igβ (CD79b) heterodimer, serving as the signal transducing component 
(Reth, 1992; Pleiman et al., 1994).  The mIg molecule consists of two heavy chains, 
cross-linked via disulfide bonds, and two light chains, each covalently bound to a heavy 
chain. At the N-terminus both heavy and light chains carry a variable (V) domain, which 
binds antigen; at the C terminus they possess a constant (C) domain, which binds to Fc 
and complement receptors (Williams & Barclay, 1988; Schroeder & Cavacini, 2010).  
The variable domains are generated by somatic recombination, a gene rearrangement 
event where V(D)J gene segments are joined together to produce a V region with a 
defined antigen specificity (Tonegawa, 1983); and are diversified by somatic 
hypermutation, a process whereby mutations increasing the affinity of the B cell receptor 
for the antigen are introduced (Di Noia & Neuberger, 2007). The C domain of the heavy 
chain (CH) determines the antibody isotype, which can be either IgM, IgG, IgD, IgE or IgA, 
with each isotype having different effector functions (reviewed by(Schroeder & Cavacini, 
2010). The CH gene is joined to the V(D)J region after the recombination of the latter has 
taken place. In naïve B cells the μ gene of the constant region (Cμ), located at the VH 
proximal end of the CH gene cluster, is expressed, thereby giving rise to an IgM type of 
BCR. After antigenic stimulation, an activated B cell may undergo class-switch 
recombination, a process which replaces the Cμ gene with Cγ, Cε or Cα, resulting in a 
new isotype of antibody (reviewed by(Honjo et al., 2002). The C domain of the light chain 
(CL) can be of only two types – λ and κ, the functional differences of which are not known 
(Reth, 1992). The gene rearrangement processes in heavy and light chains are regulated 
by a mechanism known as allelic exclusion, which ensures that only one type of 
rearranged IgH and IgL is produced, giving rise to an Ig molecule with two identical 
antigen-binding sites (for review, see(Bergman & Cedar, 2004).  
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The cytoplasmic tails of Ig molecules are relatively short, therefore the signal-transducing 
component in form of Igα and Igβ is needed (Sanchez et al., 1993; Teh & Neuberger, 
1997). The cytoplasmic domains of Igα and Igβ contain the immunoreceptor tyrosine-
based activation motifs (ITAMs) with a consensus sequence of D/Ex7D/ExxYxxLx7YxxI/L 
(Reth, 1989). These motifs are essential for signal transduction, since they become 
tyrosine phosphorylated by the BCR-associated protein tyrosine kinases (PTKs) (Gold et 
al., 1991), and recruit Src-homology 2 (SH2) domain-containing cytosolic effector proteins 
(Flaswinkel & Reth, 1994; Kurosaki et al., 1995).  
The assembly of the functional BCR complex at the cell surface is a critical step for B cell 
development. The rearrangement of the heavy chain gene takes place first. The heavy 
chain starts to be expressed at the plasma membrane at the precursor (pre)-B cell stage, 
while the light chain remains in germline configuration. Instead of the conventional light 
chain, a complex of surrogate light chains λ5 or VpreB can associate with the heavy chain 
(Tsubata & Reth, 1990) in pre-B cells. Signaling through this pre-BCR complex induces B 
cell proliferation and rearrangement of the light chain (Reth et al., 1987), allowing the 
developmental transition from pre-B cell stage to immature B cells to take place (for 
review, see(Melchers et al., 2000). Immature B cells migrate out of the bone marrow, 
where the initial steps of maturation take place, and enter the spleen, where they go 
through intermediate stages of maturation, known as T1 (transitional type 1) and T2 
(transitional type 2), before they become mature B cells. The transitional B cell subsets 
differ in their location within the spleen, and in surface expression of some markers 
(reviewed by(Chung et al., 2003). Following their exit from the bone marrow, transitional B 
cells, which encounter self-antigens in the periphery, are programmed for deletion by 
apoptosis or anergy (reviewed by(Goodnow et al., 2010). B cell repertoire selection is 
regulated by the strength of BCR signaling and by the interaction of transitional B cells 
with survival factors, such as BAFF (B cell activation factor of the TNF family) (reviewed 
by(Mackay et al., 2003). As T2 cells become mature B cells, they downregulate their 
surface IgM and upregulate surface IgD expression and move to the B-cell follicles in the 
spleen.  
Pre-BCR/BCR signaling regulates B cell fate at all developmental stages. The BCR 
signaling cascade starts with the interaction of the BCR with the antigen (or ligand-
independent receptor clustering), and subsequently diverges into multiple branches, which 
operate at different stages of B cell development and determine cellular responses.  
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2.2 The initiation of BCR-induced Ca2+ signaling 
As mentioned above, interaction of an antigen with the BCR transmits signals to the 
interior of the cell leading to activation of PTKs and phosphorylation of ITAMs on Igα and 
Igβ. It is not exactly clear how antigen binding to the extracellular domain of the BCR 
induces these changes in the intracellular domains. It is thought that antigen binding 
induces a conformational change in the BCR structure; however, the nature of this 
conformational change remains to be elucidated. Both soluble and membrane bound 
antigens can activate B cells in vitro, even though it is believed that in vivo B cells are 
activated predominantly by membrane-bound antigens (Carrasco & Batista, 2006). 
Moreover, it has been observed that monovalent antigens provided in solution cannot 
activate B cells (Landsteiner, 1924; Fanger et al., 1970; Feldmann, 1972; Minguet et al., 
2010). Therefore it is thought that B cell activation is mediated by multivalent antigens, 
which results in clustering of several BCR complexes at the cell surface upon antigen 
binding, known as the cross-linking model (Metzger, 1992). Upon cross-linking, the BCRs 
translocate into the sphingolipid and cholesterol-rich microdomains in the plasma 
membrane, known as lipid rafts (Cheng et al., 1999). According to an alternative model, 
several BCR molecules exist in oligomeric state on the cell surface, and antigen binding 
results in their dissociation, which is then translated to the intracellular signaling proteins 
(Schamel & Reth, 2000; Reth, 2001).  
Whatever the nature of the conformational change in the BCR structure is, it triggers the 
activation of several PTKs (Burkhardt et al., 1991; Gold et al., 1991). One of the earliest 
kinases to be activated is Lyn, a Src family tyrosine kinase, which is associated with the 
BCR complex and phosphorylates tyrosine residues in the ITAMs of Igα and Igβ 
(Yamanashi et al., 1991; Campbell & Sefton, 1992; Yamanashi et al., 1992; Yamamoto et 
al., 1993). Phosphorylation of ITAMs leads to the assembly of spatially resolved signaling 
complexes in the lipid rafts, sometimes referred to as micro-signalosomes (Treanor et al., 
2009). The phosphorylated ITAMs serve as docking sites for the tandem SH2 domains of 
intracellular kinase Syk, thereby recruiting it to the BCR (Wienands et al., 1995; Futterer et 
al., 1998). Moreover, binding of Syk to phosphorylated Igα/β stimulates its kinase activity 
and results in Syk autophosphorylation (Rowley et al., 1995). This is related to relieving 
the inhibition by the tandem SH2 domains, which mask the catalytic domain in the resting 
state (Tsang et al., 2008). The substrate for Syk is adaptor protein SLP65 (SH2 domain-
containing leukocyte adaptor protein of 65 kDa), also known as BLNK (B-cell linker) or 
BASH (B-cell adaptor containing an SH2 domain) (Fu et al., 1998; Wienands et al., 1998). 
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It is a cytosolic adaptor protein, which translocates to the plasma membrane and links the 
signals from BCR engagement to several intracellular effector proteins. SLP65 interacts 
with many components of the BCR signaling pathway, including Vav, Nck, Grb2 (for 
review, see(Koretzky et al., 2006); but most importantly, it recruits and forms a complex 
with Btk and PLCγ2 (Hashimoto et al., 1999; Ishiai et al., 1999b), which are enzymes, 
mediating the release of the key secondary messenger Ca2+ in B cells. In this trimolecular 
complex, known as the Ca2+ initiation complex, Btk comes in close proximity to PLCγ2 and 
can phosphorylate and activate it (Takata & Kurosaki, 1996). SLP65 therefore regulates 
both the assembly and the membrane targeting of this complex (Ishiai et al., 1999a; Su et 
al., 1999; Chiu et al., 2002; Engelke et al., 2007). Btk additionally uses its pleckstrin-
homology (PH) domain for membrane targeting, which binds phosphatidyl inositol 
triphosphate (PI(3,4,5)P3), a phospholipid generated by the action of the PI3 kinase upon 
activation of the BCR co-receptor CD19 (Scharenberg et al., 1998). Activated PLCγ2 
catalyses the hydrolysis of phosphatidyl inositol 4,5-bisphosphate (PI(4,5)P2) to secondary 
messengers inositol triphosphate (IP3) and diacylglycerol (DAG) (Hempel et al., 1992; 
Kurosaki et al., 2000). IP3 binds to IP3 receptors (IP3Rs) in the membrane of the 
endoplasmic reticulum (ER), which are Ca2+ channels that open upon IP3 binding. This 
results in a flux of Ca2+ according to its gradient from ER to the cytosol (for review, 
see(Patterson et al., 2004). Depletion of Ca2+ in the intracellular stores is sensed by 
STIM1, an ER resident transmembrane protein, which multimerizes and associates with 
store-operated Ca2+ channels (SOCs) in the plasma membrane, resulting in their 
activation (Baba et al., 2006). This leads to opening of these channels and Ca2+ influx 
from the extracellular space (for review, see(Parekh & Penner, 1997; Putney & Ribeiro, 
2000).  
2.3 BCR-induced downstream signal transduction pathways and B cell fate 
The secondary messengers generated by PLCγ2 mediate activation of downstream 
signaling cascades: activation of mitogen-activated protein kinases (MAPKs), such as the 
extracellular signal-regulated kinase (ERK), the c-Jun N-terminal kinase (JNK) and the 
p38 kinase; and transcription factors, such as the nuclear factor of activated T cells 
(NFAT) and the nuclear factor-κB (NF-κB). These different signaling pathways regulate 
survival, proliferation, differentiation and apoptosis of developing B cells (for review, 






Figure 2.1 A simplified scheme of the key signaling events in the BCR signal transduction 
pathway. 
Upon antigen binding BCR molecules on the cell surface are cross-linked (not shown) and the 
PTKs Lyn and Syk are activated. Lyn phosphorylates ITAM residues in Igα and Igβ, and Syk is 
recruited to phosphorylated ITAMs. Syk phosphorylates adaptor protein SLP65, which acts as a 
scaffold for the assembly of the Ca2+ initiation complex, consisting of SLP65, Btk and PLCγ2. Btk 
phosphorylates and activates PLCγ2. Activated PLCγ2 hydrolyses the membrane lipid PI(4,5)P2 
into secondary messengers IP3 and DAG. IP3 binds to IP3Rs at the ER membrane and initiates 
Ca2+ influx from the ER, followed by Ca2+ influx from the extracellular space. Ca2+ and DAG then 
activate downstream signaling pathways, such as the MAPK ERK, and the transcription factors 
NFAT and NF-κB.  
 
Ras/ERK pathway 
BCR engagement leads to plasma membrane recruitment and activation of small GTPase 
Ras. This is mediated by two mechanisms: via the Guanine nucleotide exchange factor 
(GEF) Sos and adaptor protein Grb2, which assemble at the activated BCR (Saxton et al., 
1994), possibly recruited there via the interaction of Grb2 with SLP65 (Fu et al., 1998); 
and/or via another GEF for Ras, RasGRP3, which is recruited to the plasma membrane by 
means of its interaction with the PLCγ2 product DAG (Oh-hora et al., 2003). Once 
activated, the GTP-bound Ras binds and activates Raf-1 and B-Raf, which phosphorylate 
and activate MEK1/MEK2, which in turn phosphorylate ERK1/ERK2. Phosphorylated 
ERKs dimerize and translocate to the nucleus, where they phosphorylate and thereby 































see(Kurosaki et al., 2010). Erk kinases play important role in B cell development, since 
they have been demonstrated to be required for transition of pro-B cells to pre-B cells and 
pre-BCR mediated cell expansion (Yasuda et al., 2008). The ERK pathway is also 
important for the survival of mature B cells (Richards et al., 2001).   
PKC-β/NF-κB pathway 
Another enzyme recruited to the plasma membrane via its interaction with the PLCγ2 
product DAG is the serine/threonine kinase PKC-β. It is activated by Ca2+ binding and 
phosphorylates the adaptor protein CARMA1 (Sommer et al., 2005). Phosphorylation of 
CARMA1 enables its association with two other adaptors Bcl10 and MALT1. This leads to 
the recruitment of kinase TAK1 to CARMA1, which phosphorylates the IKK complex 
(Shinohara et al., 2005). The activated IKK complex can then phosphorylate the inhibitor 
of NF-κB (IκB), leading to its dissociation from NF-κB (Saijo et al., 2002; Su et al., 2002; 
Shinohara et al., 2005). This leads to nuclear translocation of NF-κB, where it activates 
the transcription of NF-κB-regulated genes. NF-κB signaling is important for survival of B 
cells, since genetic ablation of upstream activators of NF-κB in mice makes B cells prone 
to apoptosis (Kaisho et al., 2001). NF-κB target genes encode many different cytokines 
and chemokines, receptors for immune recognition, proteins involved in antigen 
presentation, etc., making the NF-κB family of transcription factors the central mediator of 
immune response (for review, see(Pahl, 1999).  
Calcineurin/NFAT pathway 
Increased cytosolic Ca2+ concentration is also sensed by the key Ca2+ sensor Calmodulin, 
which activates several target molecules, including the serine/threonine phosphatase 
Calcineurin. Calcineurin dephosphorylates the transcription factor NFAT in the cytosol, 
which leads to its translocation to the nucleus and activation of NFAT-responsive genes 
(for review, see(Crabtree & Olson, 2002). B cells express three NFAT members, NFATc1, 
NFATc2 and NFATc3 (Timmerman et al., 1997). Even though mice deficient for each 
NFAT member have been described, the B cell-specific phenotype of NFAT deficiency 
has not been reported (Peng et al., 2001). As shown by the B cell-specific ablation of the 
regulatory subunit of Calcineurin, the Calcineurin/NFAT signaling pathway appears to be 
not essential for the development and maintenance of B cells, but necessary for plasma 
cell differentiation, suggesting that this signaling pathway has a modulatory role in B cell 
responses (Winslow et al., 2006).  
2 Introduction 
16 
2.4 The role of the adaptor protein SLP65 in B cell activation 
The signaling pathways downstream of the B cell antigen receptor need to be tightly 
regulated in order to control B cell responses. Adaptor proteins play important roles in the 
regulation of signaling cascades. Even though they lack enzymatic activities, adaptor 
proteins can control localization and assembly of signaling complexes, thereby linking 
enzymes with their substrates. One such “signal integrator” is the adaptor protein SLP65. 
It transmits signals from the BCR to the cytosolic effector molecules and links the BCR-
activated Syk kinase to downstream signaling pathways.  
SLP65 is expressed at all stages of B cell development starting from the pro-B cell stage 
(Pappu et al., 1999). The functional importance of this protein has been demonstrated by 
a number of studies. The function of SLP65 was first analyzed in DT40 chicken B cell 
lymphoma line. SLP65-deficient DT40 cells show no increase in cytosolic Ca2+ 
concentration and fail to activate the PLCγ2/IP3 pathway upon BCR stimulation. Loss of 
SLP65 also compromised ERK activation and abolished JNK and p38 activation in DT40 
cells (Ishiai et al., 1999a). In mice, SLP65 deficiency results in an incomplete block of B 
cell development. An increased number of pre-B cells in the bone marrow, a reduced 
number of immature B cells in the periphery, and a complete absence of mature B cells 
were observed in slp65-/- mice (Jumaa et al., 1999). B cells of these mice are also 
reported to have strongly compromised Ca2+ mobilization and to be less-responsive to 
proliferation induced by B cell mitogens (Jumaa et al., 1999; Xu et al., 2000). Moreover, 
slp65-/- mice show an impaired immune response to T-cell-independent, but not to T-cell-
dependent antigens (Xu et al., 2000), and have strongly reduced serum levels of IgM, but 
not IgG antibodies (Jumaa et al., 1999). The mouse phenotype of SLP65 deficiency is 
similar to that of SLP65-deficient human patients, who exhibit a block in pro- to pre-B cell 
transition and have no mature B cells, resulting in immunodeficiency (Minegishi et al., 
1999). Interestingly, the phenotypes of SLP65 deficiency in mice and human closely 
resemble that of X-linked agammaglobulinemia, a disease associated with the loss of Btk 
expression (Xu et al., 2000), indicating that SLP65 and Btk are involved in the same 
signaling pathway. However, since the inhibition of B cell function and development in 
SLP65 deficient mice and human patients is incomplete, it is likely that the role of SLP65 
in B cell activation is partially redundant, and it can be compensated for by other signaling 
elements.  
The main function of SLP65 in BCR signaling is a scaffolding one; it orchestrates the 
assembly and membrane targeting of the Ca2+ initiation complex (SLP65/Btk/PLCγ2), and 
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recruits other effector proteins to the BCR. This role of SLP65 is dependent on its 
tyrosine-phosphorylation. SLP65 is phosphorylated at 5 tyrosine residues by Syk kinase – 
Y72, Y84, Y96, Y178 and Y189 (positions correspond to human SLP65) (Chiu et al., 
2002). Phosphorylation of SLP65 creates docking sites for SH2 domain-containing 
signaling proteins Vav (Y72), Nck (Y72), Btk (Y96) and PLCγ2 (Y178 and Y189) (Fu et al., 
1998; Hashimoto et al., 1999; Su et al., 1999). More recently, another phospho-tyrosine 
residue in SLP65, Y119, was reported and found to bind the C2 domain of PLCγ2 
(Engelke et al., 2013). As mentioned earlier, interaction of SLP65 with Btk and PLCγ2 
enables PLCγ2 activation and Ca2+ mobilization. Interactions of SLP65 with Vav, Nck and 
Grb2 are believed to have regulatory effects on BCR signaling and link BCR ligation to 
cytoskeletal rearrangements and MAPK activation (Fu et al., 1998; Johmura et al., 2003; 
Oellerich et al., 2011). A mutant variant of SLP65 with Y to F substitutions in the 5 
phosphorylation sites (YallF), making it unable to be phosphorylated by Syk, cannot 
activate PLCγ2, and shows compromised Ca2+ and NFAT responses upon BCR-
stimulation. This indicates that phosphorylation of SLP65 bridges Syk activation to BCR-
downstream signaling cascades (Fu et al., 1998). Interestingly, the phosphorylation-
deficient and signaling-incompetent variant YallF can still be recruited to the plasma 
membrane upon BCR stimulation. This indicates that phosphorylation of SLP65 is 
independent from and downstream of plasma membrane translocation (Goldbeck, 2007). 
Dephosphorylation of signaling effectors by BCR-associated phosphatases plays an 
important role in negative regulation of BCR signaling. Dephosphorylation of SLP65 is 
mediated by SHP1, which is recruited to the inhibitory co-receptor of BCR CD22 (Gerlach 
et al., 2003).  
Even though the importance of SLP65 for BCR signaling and B cell activation in general 
has been long recognized, it is not fully comprehended how SLP65 communicates to the 
activated BCR. Several studies of our and other groups have contributed to the 
understanding of SLP65 activation and membrane recruitment process and are described 
in the next section(s). 
2.5 The membrane recruitment process of SLP65  
SLP65 is a multi-domain protein with an N-terminal positively charged region, followed by 
a central domain containing several proline-rich motifs and inducibly phosphorylated 





Figure 2.2 Domains and interaction partners of SLP65 involved in membrane targeting. 
At the N terminus, SLP65 has a positively charged region, proposed to form a leucine zipper, the 
ligand of which is unknown. The central domain contains inducibly phosphorylated tyrosines and 
proline-rich regions, the latter mediating interaction with adaptor CIN85. The C-terminal SH2 
domain binds to the phosphorylated Y204 in the BCR subunit Igα. 
 
The N-terminal region of SLP65 contains several positively charged residues, such as 
lysines and arginines, interspersed by hydrophobic amino acids, such as leucines and 
isoleucines. Based on the amino acid sequence and mutational analysis, a leucine zipper 
motif has been proposed in the N terminus of SLP65. It was found to confer some degree 
of general membrane association to SLP65 in B cells and when ectopically expressed in 
other cell types. Amino acid exchanges of residues L18 and I25, inactivating the putative 
leucine zipper motif, have been reported to abolish the membrane association of SLP65 
and the respective single point mutants couldn’t relieve the developmental block when 
expressed in mouse slp65-/- pre-B cells (Kohler et al., 2005). However, no ligand for the 
proposed leucine zipper motif in SLP65 N terminus was identified and the respective 
mechanism of SLP65 targeting remains elusive. N. Herrmann in our lab has investigated 
the potential interaction of the SLP65 N terminus with Calmodulin and PIP (phosphatidyl 
inositol phosphate) species in vitro (Herrmann, 2009). These interactions and their 
relevance for membrane recruitment of SLP65 need to be validated in vivo.  
Another “hand” that SLP65 uses to anchor itself to the plasma membrane is its SH2 
domain. It has been shown to associate with a phosphotyrosine residue located outside of 
the ITAM motif in Igα, Y204, upon BCR ligation. This interaction was proposed to mediate 
the recruitment of SLP65 to the activated BCR directly (Engels et al., 2001; Kabak et al., 
2002). However, mice harboring the knock in mutation Y204F in their Igα show only mild 
defects in BCR signaling and B cell maturation (Patterson et al., 2006). Moreover, 









the BCR (Igα Y204) 
Plasma membrane recruitment of SLP65
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the Igα/Igβ cytoplasmic domain have indicated that SLP65 can also be recruited to the 
CD8-Igβ chimera independent of Igα (Pike & Ratcliffe, 2005). From these studies it was 
therefore concluded that the Y204-mediated recruitment of SLP65 is dispensable for 
SLP65 activation and rather amplifies signaling. Nevertheless, the SH2 domain is 
essential for SLP65 function. Mutant variants of SLP65 harboring an inactivating mutation 
within or lacking the SH2 domain completely fail to translocate to the plasma membrane 
and activate Ca2+ mobilization upon BCR engagement, when expressed in slp65-/- DT40 
cells (Abudula et al., 2007). This indicates that an additional ligand for the SLP65 SH2 
domain exists, which mediates membrane anchoring. An association of the SLP65 SH2 
domain with Syk kinase was reported, however this interaction seems to be of relevance 
for a SLP65-downstream adaptor function of Syk, and not for the plasma membrane 
recruitment process of SLP65 (Abudula et al., 2007). 
A quantitative mass spectrometry approach has been used by our group to map SLP65 
interactions in real time. Numerous constitutive and inducible SLP65 ligands were 
identified. Moreover, the kinetics of their association with SLP65 was monitored, which 
allowed to distinguish between early and late binding partners. In this study, the protein C 
type lectin 17A (CLEC17A) was identified as one of the early and most dynamic SLP65 
interaction partners in DT40 cells (Oellerich et al., 2011). CLEC17A was found to be 
phosphorylated upon BCR ligation and interact with the SH2 domain of SLP65 (Von Spee, 
2010). In my Master’s thesis project I investigated the role of CLEC17A in B cell activation 
and generated a clec17a-/- DT40 cell line. The BCR-proximal signaling events, such as the 
translocation of SLP65 to the plasma membrane and the Ca2+ mobilization, were not 
affected in CLEC17A-deficient cells, indicating that this protein is not essential for the 
membrane targeting of SLP65 (Pirkuliyeva, 2012). The missing link between the SLP65 
SH2 domain and the BCR therefore still remains to be elucidated. 
The interactome analysis of SLP65 has also identified another adaptor molecule, Cbl-
interacting protein of 85 kDa (CIN85), as a constitutive interaction partner and critical 
helper for the membrane translocation of SLP65. The interaction between the two proteins 
was found to be mediated by the 3 SH3 domains of CIN85 and 3 proline-rich motifs in 
SLP65. A mutant variant of SLP65 with inactivating mutations in the 2nd and 3rd proline-
rich regions (SLP65 M23), making it unable to bind CIN85, could not efficiently translocate 
to the plasma membrane and support BCR-induced Ca2+ mobilization and NF-κB 
activation (Oellerich et al., 2011). Analysis of CIN85 localization by total internal reflection 
microscopy (TIRF) has shown that it colocalizes with the BCR-containing microclusters at 
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the cell surface in DT40 cells, moreover this colocalization was independent of SLP65 
(Oellerich et al., 2011; Bremes, 2012). In mice, B cell-specific ablation of CIN85 leads to 
defective NF-κB activation and reduced T cell-independent type II antibody responses 
(Kometani et al., 2011). However, the BCR-proximal responses, such as tyrosine 
phosphorylation and Ca2+ mobilization, are unimpaired. This can be attributed to the 
functional redundancy between CIN85 and CD2AP (CD2-associated protein), adaptor 
protein also expressed in B cells with similar domain architecture, which is able to partially 
substitute CIN85 function (Bremes, 2012). It is not clear how CIN85 aids membrane 
translocation of SLP65, or how the BCR-localization of CIN85 itself is achieved. 
Association of CIN85 with phosphatidic acid (PA), a lipid generated by the action of 
enzyme phospholipase D (PLD), has been reported (Zhang et al., 2009) and could 
contribute to the membrane localization of CIN85 in BCR-stimulated cells. Further 
investigation of the subcellular localization of CIN85 and its interaction partners in B cells 
is needed to comprehend its role in BCR signaling and SLP65 activation. 
Collectively, the studies on membrane recruitment of SLP65 have shown that it is a 
complex process, requiring cooperation of multiple domains and interaction partners of 
SLP65.  
2.6 Lessons learned from T cells: membrane targeting of SLP76 
SLP65 has a functional homologue in T cells, the cytosolic adaptor protein SLP76 (SH2 
domain-containing leukocyte adaptor protein of 76 kDa). SLP76 has only about 30% 
sequence homology, but similar domain structure to SLP65 (for review, see(Koretzky et 
al., 2006). SLP76 was first discovered as a substrate of the Syk-family PTK, ZAP-70, 
downstream of the T cell antigen receptor (TCR) (Bubeck Wardenburg et al., 1996). It 
transduces signals from the activated TCR to the intracellular signaling elements in a 
similar manner to SLP65 by mediating the assembly of the Ca2+ initiation complex, 
consisting of SLP76, PLCγ1 and Itk (for review, see(Koretzky et al., 2006). Likewise, the 
overexpression of SLP76 in the Jurkat T cell line has a positive regulatory effect on TCR 
signaling (Bubeck Wardenburg et al., 1996; Motto et al., 1996), while deficiency of SLP76 
leads to down-regulation of PLCγ1 activity and Ca2+ mobilization, resulting in defective 
ERK and NFAT activation (Yablonski et al., 1998).  
Even though the SLP adaptors share functional and structural similarities, and have 
overlapping sets of interaction partners, they use different modes of translocation to their 
site of action. Plasma membrane recruitment of SLP76 is mediated via a transmembrane 
2 Introduction 
21 
adaptor protein called linker for activation of T cells (LAT). LAT constitutively localizes to 
the glycolipid-enriched microdomains in the plasma membrane due to its transmembrane 
domain and palmitoylation at two cysteine residues in the N-terminus (Zhang et al., 
1998b; Zhang et al., 1999). Recent studies have shown that a fraction of LAT is also 
found in intracytoplasmic vesicles, which traffic between their intracellular location and the 
cell surface (Bonello et al., 2004; Purbhoo et al., 2010). LAT is phosphorylated on several 
tyrosine residues by the TCR-activated kinase ZAP-70 (Zhang et al., 1998a) and upon 
phosphorylation recruits several SH2 domain-containing proteins, including Gads (Grb2-
related adaptor protein). Gads uses its SH3 domain to constitutively associate with a 
proline-rich region in SLP76 (Liu et al., 1999). Phosphorylation of LAT therefore results in 
the recruitment of the Gads-SLP76 complex to the TCR.  
Following identification of LAT as the critical signal transducer in TCR signaling and the 
linker for membrane anchoring of SLP76, a similar molecule was predicted to exist in B 
cells. The search has identified one promising candidate, a transmembrane adaptor 
structurally related to LAT, which was named Linker of activated B cells (LAB) or Non-T 
cell activation linker (NTAL). This protein undergoes inducible tyrosine phosphorylation 
upon BCR engagement and interacts with several signaling molecules, including Grb2 
and Sos. Moreover, NTAL can partially rescue the phenotype of LAT deficiency, when 
expressed in a lat-/- Jurkat T cell line (Brdicka et al., 2002; Janssen et al., 2003). Based on 
these studies, it was proposed that NTAL could recruit SLP65 via Grb2, like LAT recruits 
SLP76 via Gads. However, further investigations have shown that NTAL does not 
represent a direct functional analog of LAT. NTAL indeed positively regulates Ca2+ 
mobilization in B cells, but it doesn’t nucleate the formation of the Ca2+ initiation complex.  
Instead, LAT forms a functional complex with Grb2 and relieves the Grb2-mediated 
inhibition of Ca2+ mobilization. Moreover, no association of NTAL with SLP65 or PLCγ2 
has been reported and it was shown that NTAL mediates its regulatory function without 
affecting SLP65 and PLCγ2 phosphorylation (Stork et al., 2004).  
Presumably due to the different modes of plasma membrane recruitment, SLP65 and 
SLP76 cannot functionally substitute each other. SLP76 cannot rescue the phenotype of 
SLP65 deficiency when expressed in slp65-/- B cells and vice versa (Ishiai et al., 2000; 
Abudula et al., 2007). However, co-expression of SLP76 and LAT in slp65-/- DT40 cells 
does restore the elevation of cytosolic Ca2+ and activation of MAPKs (Wong et al., 2000). 
This indicates that the anchors that SLP65 uses for membrane attachment cannot be 
used by SLP76. In support of this hypothesis, modification of SLP76 to enable it to bind 
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the SLP65-interaction partner CIN85, which contributes to SLP65 membrane 
translocation, renders SLP76 partially functional in slp65-/- DT40 cells (Oellerich et al., 
2011). Thus, it appears that different pathways evolved for the membrane targeting of 
SLP65 and SLP76, specified by the non-common interaction partners of the two proteins. 
2.7 Aims of this work 
The adaptor protein SLP65 plays an essential role in B cell activation and development, 
as demonstrated by the studies of SLP65-deficient mice and human-patients. SLP65 is 
involved in the initiation of BCR signaling, where it coordinates the assembly of the Ca2+ 
initiation complex at the plasma membrane. In order to carry out its function, SLP65 
relocates from the cytosol to the cell surface upon BCR ligation. The mechanism of this 
membrane translocation is not entirely clear. The main goal of this thesis is to elucidate 
the molecular details of SLP65 membrane recruitment. In order to understand the 
membrane targeting process of SLP65 I address the following questions and issues: 
1) What is the contribution of the individual domains of SLP65 for plasma membrane 
recruitment, and how do they cooperate for efficient targeting of SLP65? How does 
the molecular structure of SLP65 relate to its function? In order to investigate this 
aspect, a collaboration with the group of Prof. Griesinger at the Max-Planck 
Institute for Biophysical Chemistry is established and the secondary and tertiary 
structure of SLP65 is analyzed by NMR.  
2) What is the molecular mechanism, by which the N-terminal region of SLP65, 
predicted leucine zipper, supports membrane targeting of SLP65 and what is the 
respective ligand? Is the N terminus of SLP65 required for all stages of B cell 
development? In order to study the function of the SLP65 N terminus, different 
point mutants of SLP65 are expressed and analyzed in SLP65-deficient B cell lines 
and mouse primary B cells. The reported interactions of the N terminus with 
Calmodulin and PIPs are investigated by means of biochemical assays, such as 
immunoprecipitation and liposome floatation.  
3) What is the nature and relevance of pre-formed signaling complexes containing 
SLP65 and CIN85 in resting B cells? To answer this question, the subcellular 
distribution of SLP65 variants in resting and stimulated cells is investigated using 










CD spectrometer Chirascan  Applied Photophysics 
Cell culture incubator HeraCell 150 Heraeus 
Cell counter Countess™ Invitrogen 
Chemi Lux Imager Intas systems 
Confocal laser scanning microscope TCS SP2 Leica 
DynaPro MSXTC Wyatt technology 
Electrophoresis power supply EPS 301 Amersham Biosciences 
Electrophoresis system SDS-PAGE Bio-Rad 
Electrophoresis system Agarose gels Peqlab 
Incubator Kelvitron® t Heraeus 
Incubator Unitron Plus INFORS 
Laminar flow hood HERA safe Heraeus 
Light microscope TELAVAL 31 Zeiss 
Microplate reader PowerWave 340 BioTek  
NanoDrop 2000 Thermo Scientific 
PCR thermocycler Eppendorf 
pH-meter InoLab® 
Rocking shaker  Neolab 
Semi-dry transfer unit TE 77 GE Healthcare  
Shaker GFL 
Sonicator Bandelin Sonoplus 
Table top centrifuge 5417R Eppendorf 
Thermomixer comfort  Eppendorf 
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Ultracentrifuge Sorvall Discovery M150 SE Thermo scientific 
UV-illuminator Intas systems 
Vortex Genie 2  Scientific industries 
Water purification system Milli-Q Milipore ™ Sartorius 
Waterbath Schütt Labortechnik 
3.1.2 Software 
Description Application 
Corel DRAW X5 Graphic editing 
Dynamics V6 DLS data processing 
Endnote X4 Bibliography editing 
FACS Diva Flow cytometry analysis 
FlowJo Flow cytometry analysis 
Image J  Image processing and analysis 
Leica confocal software Confocal image processing 
Microsoft Office Text and figure editing  
OriginPro 8.5 G DLS data analysis 
pDRAW 32 DNA sequence analysis 
ZEN 2011 Confocal image processing 
3.1.3 Consumables 
Description Manufacturer 
Blotting Paper Whatman™ GE Healthcare  
Cell culture equipment (pipettes, cryo tubes, 
culture dishes)  
Greiner bio-one 
70 μm Cell strainer BD Falcon 
Chromatography columns Bio-Rad 
Dialysis tubing SERVAPOR ® Serva 
4-well imaging chambers Lab Tek 
Imaging dishes MoBiTec 
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MACS columns (LS) Miltenyi Biotec 
Nitrocellulose membrane Hybond ECL  Amersham Biosciences 
PCR tubes Sarstedt 
Pipettes Gilson 
Pipette tips Greiner bio-one 
1.5 and 2 ml tubes Greiner bio-one 
15 and 50 mL tubes Falcon 
3.1.4 Chemicals and reagents 
Reagent  Manufacturer 




Ammonium chloride Roth 
Ammonium persulfate (APS) Roth 
Bovine Serum Albumin (BSA) powder Serva 
BSA solution NEB 
Bromophenol blue Merck 
Calcium chloride Merck 
Chicken Serum Sigma 
Chloroform Roth 
Coomassie Brilliant Blue R-250 Roth 
Dimethylsulfoxide (DMSO) Roth 
DNA Ladder GeneRulerTM 1 kb Fermentas 
DNA 6X loading dye Fermentas 
Di-oleoyl phosphatidylcholine (DOPC) Sigma 
Di-oleoyl phosphatidylethanolamine (DOPE) Sigma 
Ethylenediamine-tetraacetic acid (EDTA) Roth 
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Ethidium Bromide Roth 
Ethanol Roth 
Fetal Calf Serum (FCS) Biochrom 
D-glucose Roth 





Hydrogen peroxide Roth 
Indo-1 Molecular Probes 
Igepal ® CA-630 (NP-40) Sigma 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Roth 
Isopropanol Roth 
Kanamycin Roth 
Lipopolysaccharide (LPS)  Sigma 
Luminol Sigma 
β-Mercaptoethanol Roth 
Magnesium chloride Roth 
Methanol Roth 
Deoxynucleotide solution set (dNTPs) NEB 
Nycodenz Sigma 
Quinacrine Sigma 
Para-hydroxycoumaric acid Sigma 
Penicillin/Streptomycin Sigma 
Phosphatidyl choline (PC) Avanti Polar Lipids 
Phosphatidyl ethanolamine (PE) Avanti Polar Lipids 
Phosphatidyl serine (PS) Avanti Polar Lipids 
Pluronic acid Molecular Probes 
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Polybrene (Hexadimethrine bromide) Sigma 
Potassium chloride Roth 
Potassium dihydrogen phosphate Merck 
Prestained Protein Marker NEB 
Protease Inhibitor Cocktail (P2714) Sigma-Aldrich 
Protein A/G Agarose beads Santa Cruz 
Puromycin InvivoGen 
Sephadex G-50 Sigma 
Sodium azide Roth 
Sodium cholate Sigma 
Sodium chloride Roth 
Sodium dihydrogen phosphate Roth 
Sodium dodecyl sulphate (SDS) Roth 
Sodium fluoride Roth 
Sodium hydroxide Roth 
2x Taq Master Mix Quiagen 
Trans-IT Mirus 





Yeast extract Roth 
3.1.5 Buffers and solutions 
Description Composition 
Blocking solution 5% BSA, 0.01% NaN3 in TBS-Tween 
Blotting buffer 39 mM Glycine, 48 mM Tris, 0.0375% SDS, 0.001% NaN3, 
20% methanol 
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CD buffer 20 mM NaPO4, 300 mM NaF, pH 8.0 
Coomassie staining 
solution 
0.1% Coomassie Brilliant Blue R-250, 40% methanol, 10% 
acetic acid  
6x DNA loading buffer 10 mM Tris/HCl, pH 7.6, 0.03% Bromophenol blue, 60 mM 
EDTA, 60% glycerol 
Erythrocyte lysis buffer 144 mM NH4Cl, 17 mM Tris/HCl, pH 7.6 
HP150 buffer 20 mM HEPES, 150 mM NaCl, pH 7.4 
Krebs-Ringer bufer 
(+Ca2+) 
140 mM NaCl, 4mM KCl, 1 mM MgCl2, 10mM D-glucose, 
10 mM HEPES (1 mM CaCl2) 
Laemmli buffer  30 mM Tris/HCl pH 6.8, 100 mM DTT, 10% glycerol, 3% 
SDS, 0.02 % Bromophenol blue 
LEW buffer 50 mM NaH2PO4, 300 mM NaCl, pH 8.0 
ECL solution 
 
4 ml solution A, 400 μL solution B, 1.2 μL 30% H2O2 
    Solution A 
 
250 mg/ml Luminol in 0.1 M Tris/HCl pH 8.6 
    Solution B 1.1 g/L para-hydroxycoumaric acid in DMSO 
Lysis buffer with NP-40 0.5% NP-40, 50 mM Tris pH 8, 150 mM NaCl, 5 mM NaF, 
1 mM Na3VO4, protease inhibitors 
PBS  137 mM NaCl, 2.4 mM KCl, 4.3 mM Na2HPO4 x 12 H2O, 
1.4 mM KH2PO4, pH 7.4 
Polybrene solution 3 mg/ml Polybrene in PBS 
SDS-PAGE running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS 
Separating gel 375 mM Tris/Hcl pH 8.8, 10% acrylamide, 0.25 mM EDTA, 
0.1% SDS, 0.1% TEMED, 0.1% APS 
Stacking gel 125 mM Tris/HCl pH 6.8, 4.8 % acrylamide, 0.25 mM 
EDTA, 0.1% TEMED, 0.1% APS 
TAE buffer  40 mM Tris/acetic acid pH 7.8, 10 mM NaOAc, 1 mM 
EDTA, pH 8 
TBS-T 20 mM Tris, 137 mM NaCl, 0.1% Tween20, pH 7.6 




R-10 medium RPMI 1640 (Merck), 10% FCS, 50 U/ml penicillin, 50 µg/ml 
streptomycin 
Serum-free R-10 medium RPMI 1640 (Merck), 50 U/ml penicillin, 50 µg/ml 
streptomycin 
DT40 medium RPMI 1640 (Merck), 3 mM L-glutamine, 1% chicken 
serum, 50 U/ml penicillin, 50 µg/ml streptomycin 
Plat E medium DMEM (Merck), 10% FCS, 50 U/ml penicillin, 50 µg/ml 
streptomycin 
Freezing medium 10% DMSO in FCS 
LB medium 10 g/L trypton, 5 g/L yeast extract, 10 g/L NaCl 
LB agar 15 g Agar in 1L LB medium 
3.1.7 Enzymes 
Name Manufacturer 
Phusion High-Fidelity DNA polymerase NEB 
Pfu DNA polymerase Promega 
Calf Intestinal Phosphatase (CIP) NEB 
Type II restriction endonucleases NEB 
T4 DNA ligase NEB 
3.1.8 Ready-made reaction kits 
Description Manufacturer 
Invisorb ® Spin Plasmid Mini Two  Invitek 
Pure Yield ™ Plasmid Midiprep System Promega 
RNAeasy ® Mini Kit Qiagen 
The Original TA cloning ® Kit Invitrogen 
Wizard ® SV Gel and PCR clean up Kit Promega 
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First strand cDNA synthesis kit Fermentas 
Coomassie Plus – The Better Bradford Assay™ Reagent Thermo Scientific 
Pierce ® BCA Protein Assay Kit Thermo Scientific 
Protino ® Ni-IDA 1000 Macherey Nagel 
Penta His HRP Conjugate kit Quiagen 
Mouse B cell isolation kit Milteny Biotec 
Mini Extruder kit Avanti Polar Lipids 
3.1.9 Oligonucleotides 
All oligonucleotides were produced by Eurofins MWG Operon by the HPSF method and 
supplied as a lyophilized powder, which was subsequently reconstituted with distilled 
water to a final concentration of 100 pmol/μL.  







BglII_dNSLP65_fw TAATAGATCTGACTACGCTTCAGAGAGCCCTG cloning  
NdeI_SLP65_fw CATATGATGGACAAGCTTAATAAAATAACCG cloning  
hSlp_rev_stopXho TTCTCTCGAGTTATGAAACTTTAACTGCAT cloning  
SLP65_L18A_fw GAAGTTGAGGCAGCTTCAAAAGATG mutagenesis  








SLP65_V22A_rev GTTTTTAATATCATGGGCCATCTTTTGAAGCT mutagenesis  






































































































NotI_Cit_rev TAATGCGGCCGCTTTACTTGTACAGCTCGTC cloning  
pMSCVfw CCCTTGAACCTCCTCGTTCGACC sequencing 
pMSCVrev CAGACGTGCTACTTCCATTTGTC sequencing 
EGFP_C_fw GTCCTGCTGGAGTTCGTG sequencing 
EGFP_C_rev AGCTGCAATAAACAAGTT sequencing 
T7 TAATACGACTCACTATAGG sequencing 
3.1.10 Vectors and Constructs 
3.1.10.1 Vectors 
Vector Application Source 
pCRII   T/A cloning Invitrogen 
pHCMV-VSV-G expression of vsv-g cDNA for the production of 
recombinant retroviruses 
Dr. M. Engelke 
pMSCVpuro expression of retroviraly transduced cDNA in 
eukaryotic cells 
Clontech 
pMSCVpuro Cit expression of retrovirally transduced cDNA with 
an N-terminal Citrine tag in eukaryotic cells 
Dr. M. Engelke 
pET16b TEV expression of cDNA with an N-terminal His6 tag 
in bacteria 
Dr. S. Becker 
pGEX-4T1 expression of cDNA with a GST-tag in bacteria GE Healthcare 
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3.1.10.2 Constructs 
The constructs generated in this thesis were cloned using standard procedures described 
in the Methods section. For the generation of eukaryotic expression vectors carrying the 
cDNA of interest with an N-terminal Citrine tag, the cDNA was amplified by PCR, digested 
with BglII/BamHI and NotI restriction enzymes and ligated into the pMSCVpuro Cit vector 
digested with BglII and NotI. For the generation of prokaryotic expression vectors carrying 
the cDNA of interest with an N-terminal His6 tag, the cDNA was amplified by PCR, 
digested with NdeI and XhoI and ligated into the pET16bTEV vector digested with NdeI 
and XhoI. The mouse Amph and Asyn cDNA was first cloned into the pCRII vector and 
then sub-cloned into pMSCVpuro Cit.  
Construct Description Source 
pCRII hSLP65 Human SLP65 Dr. V. Bremes 
pMSCVpuro Cit 
hSLP65WT  
N-terminal Citrine-tag, human SLP65  Dr. M. Engelke 
pMSCVpuro Cit 
hSLP65ΔN 
N-terminal Citrine-tag, human SLP65 Δ aa 1-50  Dr. M. Engelke 
pMSCVpuro 
Citrine 
N-terminal Citrine-tag Dr. M. Engelke 
pMSCVpuro Cit 
chCaM 
N-terminal Citrine-tag, chicken Calmodulin  This thesis 
pMSCVpuro Cit 
hSLP65I25A 
N-terminal Citrine-tag, human SLP65 I25A  Dr. N. Hermann 
pMSCVpuro Cit 
hSLP65I25K 
N-terminal Citrine-tag, human SLP65 I25K  Dr. N. Hermann 
pMSCVpuro Cit 
hSLP65L18K 
N-terminal Citrine-tag, human SLP65 L18K  Dr. M. Engelke 
pMSCVpuro Cit 
hSLP65L18A 
N-terminal Citrine-tag, human SLP65 L18A  This thesis 
pET16bTEV 
hSLP65WT 
N-terminal His6-tag, human SLP65  Dr. N. Hermann 




N-terminal His6-tag, human SLP65 Δ aa 1-48  Dr. N. Hermann 
pET16bTEV 
hSLP65L18K 
N-terminal His6-tag, human SLP65 L18K  This thesis 
pET16bTEV 
hSLP65L18A 
N-terminal His6-tag, human SLP65 L18A  This thesis 
pET16bTEV 
hSLP65I32G 
N-terminal His6-tag, human SLP65 I32G  This thesis 
pET16bTEV 
hSLP65M33A 
N-terminal His6-tag, human SLP65 M33A  This thesis 
pET16bTEV 
hSLP65I36A 
N-terminal His6-tag, human SLP65 I36A  This thesis 
pCRII mAmph Mouse Amphyphisin This thesis 
pCRII mAsyn Mouse α-Synuclein This thesis 
pMSCVpuro Cit 
N-BAR-ΔNSLP65 
N-terminal Citrine-tag, mouse Amphiphysin aa 




N-terminal Citrine-tag, mouse α-Synuclein aa 1-





N-terminal Citrine-tag, BAR domain of mouse 





N-terminal Citrine-tag, human SLP65 Δ aa 1-50 





N-terminal Citrine-tag, human CIN85 1-599 




N-terminal Citrine-tag, human SLP65 M21A  This thesis 




N-terminal Citrine-tag, human SLP65 M21G  This thesis 
pMSCVpuro Cit 
hSLP65V22A 
N-terminal Citrine-tag, human SLP65 V22A  This thesis 
pMSCVpuro Cit 
hSLP65I32G 
N-terminal Citrine-tag, human SLP65 I32G  This thesis 
pMSCVpuro Cit 
hSLP65M33A 
N-terminal Citrine-tag, human SLP65 M33A  This thesis 
pMSCVpuro Cit 
hSLP65I36A 
N-terminal Citrine-tag, human SLP65 I36A  This thesis 
pMSCVpuro Cit 
hSLP65L39G 
N-terminal Citrine-tag, human SLP65 L39G  This thesis 
pMSCVpuro Cit 
hSLP65GS 
N-terminal Citrine-tag, human SLP65 with a GS 
linker between aa 50-330 (see Figure 4.2 for 




Human CIN85 aa 594-665 fused to human 
SLP65 Δ aa 1-50 with a GS linker between aa 





N-terminal Citrine-tag, human SLP65 aa 1-50, 










N-terminal Citrine-tag, human SLP65 Y96Fnew 




N-terminal GST tag, human Btk SH2 domain Dr. Niklas 
Engels 
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3.1.11 Antibodies 
3.1.11.1.1 Primary antibodies 
The antibodies were used for Western blot analysis (WB), Immunoprecipitation (IP) or 
BCR-stimulation (S). For Western blotting, primary antibodies were used at the dilution 
recommended by the supplier in TBS-T with 1% (w/v) BSA and 0.01% (v/v) NaN3. The 
antibody concentrations used for BCR-stimulation and immunoprecipitation are mentioned 
in the respective methods sections.   
Antibody Supplier Application 
α-human BLNK, mouse monoclonal IgG2a BD Biosciences WB 
α-human BLNK (#3587), rabbit polyclonal CST WB 
α-GFP, mouse monoclonal IgG1κ Roche IP, WB 
α-chicken IgM (M4) Biozol S 
α-Akt1, rabbit monoclonal CST WB 
α-Hsv2, rabbit polyclonal Dr. K. Kühnel WB 
α-human pBLNK (Y96), rabbit polyclonal CST WB 
Fab fragment goat anti-human IgM Jackson 
 
S 
Fab fragment goat anti-mouse IgM + IgG Jackson 
 
S 
α-pY (4G10), monoclonal mouse IgG2b Merck Millipore WB 
α-human PLCγ2 (Q20), rabbit polyclonal Santa Cruz WB 
3.1.11.2 Secondary antibodies 
All secondary antibodies were used for Western blotting at a 1: 10 000 dilution in TBS-T.  
Antibody Supplier 
Goat α-rabbit IgG, HRPO-conjugated Southern biotech 
Goat α-mouse IgG, HRPO-conjugated Southern biotech 
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3.1.12 Biological material 
3.1.12.1 Bacterial strains 
Strain Supplier 
One Shot ® TOP10F’ chemo-competent E.coli Life Technologies 
One Shot ® BL-21 (DE3) chemo-competent E.coli Life Technologies 
3.1.12.2 Eukaryotic cell lines 
DT40 (ATCC ®  CRL-2111™)  
The DT40 cell line is chicken B cell line, derived from an avian leucosis virus-induced  
bursal lymphoma (Baba & Humphries, 1984). It expresses IgM on the cell surface. DT40 
cells have a high ratio of targeted to random DNA integration, which allows for easy gene 
modification via homologous recombination (Winding & Berchtold, 2001). 
DG75 (DSMZ-No: ACC 83)  
The DG75 cell line was derived from a pleural effusion of a 10-year old child with Burkitt’s 
lymphoma. It expresses IgM coupled to the κ light chain on the cell surface (Ben-Bassat et 
al., 1977).  
3.2 Methods 
3.2.1 Molecular biology methods 
3.2.1.1 Polymerase Chain Reaction (PCR) 
PCR was used for the amplification of DNA fragments from cDNA or plasmid DNA, which 
were subsequently used for further cloning procedures. This method allows specific DNA 
amplification in vitro with a thermostable DNA polymerase; the method was originally 
described by (Saiki et al., 1988). PCR was set up in a total volume of 25 μL with 200 μM 
dNTPs (NEB), 0.2 μM of each primer, 1X GC buffer (NEB), 0.4 U Phusion High-Fidelity 
DNA polymerase (NEB) and 10-50 ng template DNA. The parameters for the cycler 
program are summarized below. The amplification times and annealing temperatures 
varied according to the primers and the templates used. Higher annealing temperature 
was used for GC-rich templates and primers with higher melting temperature.  
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Table 3.1 Cycler parameters for a standard PCR program. 
Step Explanation Temperature (°C) Time Number of cycles 
1 Initial denaturation 94 2 min 1 
2 Denaturation 94 30 sec 30-35 
3 Annealing 55-65 30 sec 
4 Elongation 68 30 sec to 2 min 
5 Final elongation 68 10 min 1 
6 Pause 14 ∞ 1 
3.2.1.2 Overlap extension PCR 
Overlap extension PCR was used for the fusion of two DNA fragments with overlapping 
ends. First, the two fragments were amplified with the conventional PCR using primers, 
designed to contain the overlapping ends. Subsequently, an overlap extension PCR was 
set up with 200 μM dNTPs (NEB), 1X GC buffer (NEB), 0.2 μL Phusion High-Fidelity DNA 
polymerase (NEB) and 20-100 ng of each template DNA. The following program was used 
for overlap extension PCRs: 
Table 3.2 Cycler parameters for the overlap extension PCR, part 1. 
Step Explanation Temperature (°C) Time Number of cycles 
1 Initial denaturation 94 2 min 1 
2 Denaturation 94 30 sec 15 
3 Annealing 55-58 30 sec 
4 Elongation 68 30 sec to 2 min 
5 Final elongation 68 10 min 1 
6 Pause 14 ∞ 1 
Following initial amplification of the extended template, forward and reverse primers for 
the final amplification product were added to a final concentration of 0.2 μM and the 
amplification was continued for 25-30 cycles with increasing annealing temperature to 
ensure specificity. 
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Table 3.3 Cycler parameters for the overlap extension PCR, part 2. 
Step Explanation Temperature (°C) Time Number of cycles 
1 Initial denaturation 94 2 min 1 
2 Denaturation 94 30 sec 25-30 
3 Annealing 58 + 0.2 °C/cycle 30 sec 
4 Elongation 68 30 sec to 2 min 
5 Final elongation 68 10 min 1 
6 Pause 14 ∞ 1 
An overlap extension PCR was used to generate the cDNA encoding chimeric fusion 
proteins N-BAR-ΔNSLP65, ALPS-ΔNSLP65, SLP65 GS, CC-ΔNSLP65GS and SLP65 
GS-Sykt(SH2)2.  
3.2.1.3 Site directed mutagenesis 
Site directed mutagenesis was used to introduce single point mutations into the N-terminal 
region of SLP65. Overlapping forward and reverse primers carrying the desired mutation 
were used to amplify the plasmid containing the wild type slp65 gene (pCRII SLP65) by 
conventional PCR. Pfu polymerase was used and the elongation time was set to 4 min. 
Following amplification, the PCR product was purified and treated with 1 μL DpnI 
endonuclease (NEB) for 30 min at 37 °C in order to digest the non-mutated plasmid, 
which was used as the PCR template.  
3.2.1.4 Restriction enzyme digestion 
PCR fragments and plasmids were digested with restriction endonucleases for further 
cloning applications. The digests were set up in a total volume of 25 μL with 2.5 μL 
appropriate 10X buffer (NEB), 2.5 μL 1mg/mL BSA (NEB), 0.3-1 μL restriction enzyme 
and 0.2-1 μg DNA. Digests were performed at 37 °C for 1 to 12 hours. For the digests of 
plasmid DNA with only one type of enzyme subsequent treatment with 1 μL of CIP was 
performed for 30 min at 37 °C in order to dephosphorylate the 5’ ends and prevent 
plasmid re-ligation.  
3.2.1.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate PCR products or DNA fragments 
resulting from restriction digests. 1% agarose gels (2% for the separation of fragments 
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smaller than 500 bp) were prepared in 1X TAE buffer with 0.5 μg/mL etidium bromide. The 
DNA fragments to be separated were pre-mixed with the 6X DNA loading dye 
(Fermentas) and loaded on the gel together with the 1 kb DNA ladder (Fermentas) for size 
determination. Electrophoresis was performed at 200 mA and 100 V for 20-50 min (longer 
for larger DNA fragments). An UV illuminator (Intas Systems) was used to visualize the 
DNA.   
3.2.1.6 Purification and gel extraction of DNA fragments 
PCR products and DNA fragments resulting from digestion with restriction enzymes were 
purified prior to further cloning procedures. The Wizard ® SV Gel and PCR clean up Kit 
(Promega) was used according to the manufacturer’s protocol. PCR products were either 
purified directly following PCR or separated by size on an agarose gel first. In the latter 
case, DNA bands of the appropriate size were excised from the gel with a scalpel and 
DNA was extracted from the gel according to the instructions. The DNA fragments were 
eluted in 30-100 μL Nuclease-free water (Promega). 
3.2.1.7 Ligation of DNA fragments 
For the ligation of DNA fragments, ligation mixture with a total volume of 10 μL, containing 
1X ligation buffer (NEB), ~ 20 ng digested vector DNA, ~ 50 ng digested insert DNA and 1 
μL T4 DNA ligase (NEB) was set up. The ligation mixture was incubated at 16 °C for 4 to 
12 hours.  
3.2.1.8 Cloning of PCR fragments via T/A cloning 
For cloning of PCR fragments into the PCRII vector, purified PCR fragments were 
incubated with the 2x Taq master mix for 1 hour at 72 °C in order to add “A” overhangs to 
the DNA ends. Following this treatment, PCR fragments were purified again and ligated 
into the PCRII vector according to the standard procedures described above.  
3.2.1.9 Transformation of chemo-competent E.coli 
E. coli Top10F- or BL21 competent cells (kindly prepared by Ines Heine) were thawed on 
ice. Top10F- cells were used for the amplification of plasmids while BL21 cells were used 
for protein expression. The ligation mix or 100-200 ng plasmid DNA was added onto the 
cells and incubated on ice for 20 min. Following a heat shock treatment at 42 °C for 45 
sec to 1 min, the cells were briefly incubated on ice and 200 μL antibiotic-free LB medium 
was added. The cells were subsequently incubated at 37 °C for 30 min and plated on 
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ampicillin (100 μg/ml)- or kanamycin (50 μg/ml)-containing LB plates. The plates were 
incubated at 37 °C for 12-16 hours.  
3.2.1.10 Isolation of plasmid DNA 
Single colonies were picked from bacterial plates, resuspended in LB medium 
supplemented with ampicillin or kanamycin and grown overnight at 37 °C. Plasmid DNA 
was isolated from 2-4 mL or 100-200 mL of overnight bacterial culture using either the 
Invisorb ® Spin Plasmid Mini Two kit or the Pure Yield ™ Plasmid Midiprep kit, 
respectively, according to the manufacturer’s instructions. The concentration of purified 
plasmid DNA was determined with the NanoDrop spectrophotometer (Thermo Scientific). 
1-1.2 μg plasmid DNA was sent for sequencing with an appropriate primer to Microsynth 
AG, Goettingen. 
3.2.1.11 Total RNA isolation 
Total RNA was isolated from mouse brain tissue with the RNeasy® Mini kit (Quiagen), 
according to the protocol provided with the kit. RNA was eluted in 100 μL RNase-free 
water. 
3.2.1.12 cDNA synthesis 
The RNA isolated from the mouse brain tissue was used as a template for cDNA 
synthesis. The First strand cDNA synthesis kit (Fermentas) was used to produce cDNA by 
reverse transcription. The obtained cDNA was used as a template for PCR in order to 
amplify the fragments encoding Amphiphysin and α-Synuclein lipid-binding domains. 
3.2.2 Biochemical methods 
3.2.2.1 Expression and purification of recombinant GST proteins 
E.coli BL21 cells, transformed with the GST-fusion constructs (pGEXT backbone), were 
grown overnight and diluted 1:100 in 50-200 mL LB medium supplemented with ampicillin. 
The cultures were grown at 37 °C to OD600 0.6 and protein expression was induced with 
0.1 mM IPTG. After 4 hours bacteria were harvested by centrifugation at 6000 rpm at 4 °C 
for 20 min and the pellets were resuspended in 1-4 mL PBS. For lysis, the bacteria were 
sonicated 3 times for 30 sec (5x10% cycles, 50% power). Following sonication, Triton-X 
was added to a final concentration of 0.01% and bacterial lysates were incubated on ice 
for 30 min. Subsequently, the lysates were centrifuged at 6000 rpm at 4 °C, and the 
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supernatant was used for incubation with Glutathione Sepharose beads (GE Healthcare) 
overnight, while rotating at 4 °C. The beads were washed 3 times with PBS and 
resuspended in an appropriate amount of PBS in order to get a 50-60 % (v/v) slurry 
suspension. To quantify the amount of bound GST-fusion proteins, 5 and 10 μL of slurry 
was mixed with 2X Laemmli buffer and loaded on an SDS-PAGE gel together with known 
amounts of BSA (NEB) and pre-stained protein marker (NEB). Following protein 
separation the gel was stained with Coomasie staining solution for 5-10 min while shaking 
and de-stained with tap water overnight.   
3.2.2.2 Expression and purification of recombinant His-tagged proteins 
For the expression of N-terminal His6-tagged SLP65 protein, pET16b plasmids were 
transformed into E.coli BL21. Bacterial cultures were grown as described above for the 
GST-fusion proteins. Protein expression was induced with 1 mM IPTG. After 4 hours, 
bacteria were harvested, resuspended in LEW buffer and lysed as described above. His6-
tagged proteins were purified with the Protino Ni-IDA 1000 kit (Macherey Nagel) according 
to the manufacturer’s instructions. The proteins were eluted from the column in 1 mL 250 
mM imidazole-containing LEW buffer. The proteins were dialyzed overnight against LEW 
buffer without imidazole and stored with protease inhibitors (Sigma) and 0.01% NaN3 at 4 
°C for maximum one week.  
3.2.2.3 Photometric determination of protein concentration 
For the determination of protein concentration, BCA or Bradford methods was used. 
Several dilutions of the protein of interest were prepared in the appropriate buffer. A series 
of BSA dilutions with concentrations of 0.125 to 1.5 mg/mL BSA (NEB) were prepared in 
the same buffer. The standards and protein samples were pipetted into a 96-well plate 
and an appropriate amount of Bradford (Thermo scientific) or BCA (Thermo scientific) 
reagent was added. The absorbance was measured with the microplate reader 
PowerWave 340 (BioTek) at 595 nm for the Bradford assay or at 562 nm for the BCA 
assay. A standard curve was plotted and used for calculation of protein concentrations. 
3.2.2.4 Preparation of cleared cellular lysates (CCLs) 
Cleared cellular lysates were prepared from resting and BCR-stimulated DT40 cells and 
used to analyze the protein expression level by Western blotting, or further used for 
protein immunoprecipitation or affinity purification experiments. The cells were harvested 
and washed once with PBS. 1-5 x 107 cells were resuspended in serum free R10 medium 
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and “starved” for 30 min at 37 °C, in order to reduce the basal level of protein 
phosphorylation. Following starvation, the cells were left unstimulated or were stimulated 
for different amounts of time with 2 μg/mL α-chicken IgM (M4) antibody. Stimulation was 
done at 37 °C and stopped by transferring the cells on ice. Subsequently, the cells were 
harvested at 10 000 rpm at 4 °C for 1 min, resuspended in 1 mL NP-40 lysis buffer and 
incubated for 45-60 min at 4 °C, while rotating. Following lysis, the lysates were 
centrifuged at 14 000 rpm at 4 °C for 20 min and the supernatant was transferred into a 
new Eppendorf tube. The lysates were then mixed with Laemmli buffer, incubated for 5 
min at 95 °C and loaded on a gel for analysis by immunoblotting.  
3.2.2.5 Affinity purification (AP) 
For affinity purification, 2.5-5 x 107 cells per sample were used to prepare CCLs as 
described above. Following centrifugation, 900 μL of the CCLs were incubated with 20-30 
μL of Glutathione Sepharose beads (GE Healthcare) (50% slurry suspension) bound to 
GST-fusion proteins for 4 hours, rotating at 4 °C. The beads were collected by 
centrifugation at 300 g, at 4 °C for 4 min and washed 3 times with NP-40 lysis buffer. 
Finally, the supernatant was removed and the beads were resuspended in 50 μL 2X 
Laemmli buffer. The samples were incubated at 95 °C for 5 min to elute the proteins and 
loaded on a gel for analysis by immunoblotting.  
3.2.2.6 Protein immunoprecipitation (IP) 
2.5-5 x 107 cells per sample were used to prepare CCLs, as described above. After 
centrifugation, 900 μL of the lysates were incubated with 1 μg of precipitating antibody (α-
GFP) overnight, while rotating at 4 °C. On the next day 20 μL of Protein A/G Agarose 
beads (Santa Cruz) (25% suspension) was added and the samples were incubated for 45 
min rotating at 4 °C. The beads were collected by centrifugation at 300 g, at 4 °C for 4 min 
and washed 3 times with NP-40 lysis buffer. The supernatant was removed and the beads 
were resuspended in 50 μL 2X Laemmli buffer. The samples were incubated at 95 °C for 
5 min to elute the protein from the beads and loaded on a gel for analysis by 
immunoblotting.   
3.2.2.7 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins under denaturing conditions by size, as 
originally described by Laemmli (Laemmli, 1970). The proteins were first concentrated in a 
stacking gel and then separated in a resolving gel (discontinuous SDS gel system). The 
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10% resolving gel was prepared with 10% acrylamide-bis-acrylamide (17.5:1), 375 mM 
Tris pH 8.8, 0.1% SDS, 0.001% APS and 0.001% TEMED. The 5% stacking gel was 
prepared with 5% acrylamide-bis-acrylamide (17.5:1), 125 mM Tris pH 6.8, 0.001% APS 
and 0.001% TEMED. Electrophoresis was performed in SDS-PAGE running buffer at a 
constant current of 15 mA for the stacking gel, and 30 mA for the separating gel. Pre-
stained protein marker (NEB) was loaded on the gel together with the samples for 
molecular weight determination. Following electrophoresis, the gel was subjected to 
Western blot analysis or stained with Coomasie staining solution for direct visualization of 
proteins.  
3.2.2.8 Western blot (WB) analysis 
Following the separation by SDS-PAGE, the proteins from the gel were transferred to a 
nitrocellulose membrane. A semi-dry blotting method was used. Nitrocellulose membrane 
and two pieces of Whatman paper were cut according to the size of the gel and soaked in 
Blotting buffer. The transfer apparatus was assembled as follows: anode, Whatman 
paper, nitrocellulose membrane, gel, Whatman paper, cathode. The proteins were 
transferred at 200 mA and 16 V for 1 hour. Following transfer, the blot was incubated in 
the blocking solution at RT for 1 hour. Afterwards, the blot was incubated with the primary 
antibody solution at 4 °C overnight. The next day the blot was washed 3 times for 15 min 
with TBS-T at RT. Afterwards, the blot was incubated with the secondary antibody solution 
at RT for 1 hour. Finally, the blot was washed 3 times with TBS-T and developed with 
Luminol solution using digital imaging system (Chemi Lux Imager Intas) for specific 
detection of proteins. 
3.2.2.9 Preparation of SUVs by detergent exclusion 
The preparation of liposomes with different methods and the liposome floatation assays 
were performed at the lab of Dr. K. Kühnel, using resources of the department of 
Neurobiology, Max-Planck Institute for Biophysical Chemistry. Phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) (all Avanti Polar Lipids) and 
Texas-Red labeled PE (Life Technologies) were reconstituted with chloroform to a final 
concentration of 20 mg/ml. Appropriate amounts of lipids were pipetted to a 2 mL 
Eppendorf tube with round bottom to a total lipid amount of 1 mg. Lipid films were dried at 
RT for 2 hours and either directly used for liposome preparation, or stored at -20 °C for 4-
6 weeks. The lipid films were rehydrated with 150 μL 3% sodium cholate solution in LEW 
buffer. Sephadex G-50 was resuspended in LEW buffer at a concentration of 0.05 g/mL 
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and this solution was used to pack the chromatography columns (Bio-Rad). Lipid-
detergent mixture was carefully loaded on packed columns and overlaid with 5 mL LEW 
buffer. The pink fraction containing SUVs was collected (400 – 500 μL) into an Eppendorf 
tube.  
3.2.2.10 Preparation of LUVs by extrusion 
Lipid films were prepared as described above and rehydrated with 1 mL LEW buffer. The 
liposome suspension was extruded through 400 nm and 100 nm filters with the mini 
extruder kit (Avanti Polar Lipids) using 1 mL Hamilton syringes. 
3.2.2.11 Liposome floatation  
5 μL of the recombinant His6-tagged SLP65 solution, with a protein concentration of 1-5 
μM was mixed with 45 μL SUV or LUV solution and incubated at RT for 15 min. For the 
comparison of protein binding to SUVs and LUVs, the liposome concentration was 
adjusted prior to incubation with the protein. For this purpose, the absorbance of Texas-
Red at 592 nm in SUV and LUV samples was measured with the NanoDrop 
spectrophotometer (Thermo scientific) and the more concentrated suspension was diluted 
with an appropriate amount of LEW buffer. The lipid-protein mixture was mixed with 50 μL 
80% Nycodenz solution (in LEW buffer) and transferred to ultracentrifugation 
polycarbonate tubes (Beckman). 50 μL 30% Nycodenz solution was carefully added on 
top. Finally, the gradient was overlaid with 30 μL LEW buffer. Ultracentrifugation was 
performed at 55 000 rpm at 4 °C for 90 min. Following ultracentrifugation, six fractions, 30 
μL each, were taken for analysis of protein distribution by immunoblotting, mixed with 
Laemmli buffer and incubated at 95 °C for 5 min to denature the proteins.   
3.2.2.12 Preparation of SUVs for NMR and CD spectroscopy 
For NMR and CD spectroscopy, 75% (w/v) DOPC, 25% (w/v) DOPE SUVs were used. 
The lipids for SUV preparation were kindly provided by C. Schwiegk (department of NMR-
based biology, Max-Planck Institute for Biophysical Chemistry). Lipid films were prepared 
as described above and rehydrated with 1 mL HP150 buffer for a final total lipid 
concentration of 12 mM. The lipid suspension was sonicated for 45 sec 20 times (5x10% 
cycles, 60% power) on ice. Afterwards, the sonicated lipid suspension was extruded 
through 100 nm and 50 nm filters.  
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3.2.3 Cell biology methods 
3.2.3.1 Culturing of eukaryotic cells 
All cells were passaged under the laminar flow hood (Heraeus) and cultured at 37 °C in a 
humidified atmosphere with 5% CO2. Adherent cells (PlatE) were cultured in DMEM 
medium, supplemented with 10% FCS, 50 U/mL penicillin and 50 μg/mL streptomycin. 
PlatE cells were treated with 0.05 M Trypsin/EDTA and incubated for 1 min at 37 °C prior 
to passaging. Every two weeks PlatE cells were selected with 10 μg/mL blasticidin and 2.5 
μg/mL puromycin. Suspension cells (all B cell lines and primary B cells) were cultured in 
RPMI medium, supplemented with 10% FCS, 50 U/mL penicillin and 50 μg/mL 
streptomycin (R10). For culturing of DT40 cells, R10 medium was also supplemented with 
1% chicken serum and 3 mM L-glutamine.  
3.2.3.2 Harvesting and counting of cells 
All cells were harvested by centrifugation in a table top centrifuge at RT, 1200 rpm for 4 
min unless indicated otherwise. The automated cell counter Countess™ (Invitrogen) was 
used to count the cells.  
3.2.3.3 Freezing and thawing of cells 
Cells were thawed rapidly in a water bath at 37 °C and resuspended in 10 mL R10 or 
PlatE medium. The cells were then harvested by centrifugation, resuspended in fresh 
medium and transferred to the cell culture dishes.  
For freezing, 0.5-1 x 107 cells were harvested, resuspended in 1-1.4 mL freezing medium, 
aliquoted to 2 cryo-vials and transferred on ice. The cells were frozen at -140 °C.  
3.2.3.4 Isolation of primary splenic mouse B cells 
Primary B cells were isolated from the spleens of two 8-weeks old slp65-/- mice and were 
used for retroviral transfection with SLP65 constructs. The spleens were prepared, 
homogenized with a plunger top of a syringe in a Petri dish filled with 10 mL R10, and 
passed through a 70 μm nylon cell strainer (BD Falcon). The cells were transferred to a 15 
mL Falcon tube and centrifuged at 1200 rpm at 4 °C for 6 min. The supernatant was 
discarded and the cell pellet was resuspended in 2 mL erythrocyte lysis buffer and 
incubated at 4 °C for 4 min. The reaction was stopped by the addition of 0.7 mL FCS. The 
cells were centrifuged at 1200 rpm at 4 °C for 6 min and washed once with PBS. 
Subsequently, the cells were counted and subjected to Magnetic Activated Cell Sorting 
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(MACS) using the Mouse B cell isolation kit (Miltenyi Biotec). LS MACS separation 
columns were used. Following isolation, the cells were counted again and resuspended in 
R10 medium, supplemented with 20 μg/ml LPS, at a cell density of 1 x 106 cells/mL.  
3.2.3.5 Transfection of PlatE cells by lipofection 
PlatE cells were used for the generation of infectious, replication-dependent recombinant 
retroviruses. The cells were co-transfected with the retroviral expression vector pMSCV 
containing the cDNA of interest and the pHCMV eukaryotic expression vector encoding 
the envelope glycoprotein from the vesicular stomatitis virus (VSV-G), to allow for 
production of amphotrophic viruses. One day prior to transfection PlatE cells were seeded 
on 6-cm cell culture dishes, to achieve a confluence of 50-70% at the time of transfection. 
The transfection mix, consisting of 400 μL serum-free R10 medium, 7 μL Trans-IT 
transfection reagent (Mirus), 0.5 μg pHCMV-VSV-G plasmid DNA and 2-3 μg pMSCV 
plasmid DNA, was prepared and incubated at RT for 15-45 min. The DMEM medium was 
removed from the PlatE cells and 4 mL of fresh R10 medium was added. The transfection 
mix was carefully pipetted onto the cells and the cells were incubated at 37 °C for 48 
hours.  
3.2.3.6 Retroviral transduction of DT40 and DG75 cells 
DT40 and DG75 cells were infected with recombinant retroviruses to achieve a stable 
expression of the transgene of interest. Viral supernatant was collected from transfected 
PlatE cells and centrifuged at 1200 rpm for 4 min to separate the viral particles from the 
cells. 1 x 106 cells were harvested and resuspended in 3.5-4 mL of viral supernatant. The 
cells were transferred onto 6-cm dishes and 1 ml of fresh R10 medium, supplemented 
with 3 μg/mL Polybrene, was added. The cells were incubated with the viral supernatant 
at 37 °C for 24 hours. On the next day, the viral supernatant was removed; the cells were 
resuspended in fresh R10 medium, and left to recover from infection at 37 °C for 24 hours. 
On the following day, the cells were transferred to the selection medium (R10 or DT40 
medium supplemented with 1 μg/mL Puromycin). The cells were kept on selection for 2-3 
days and subsequently transferred to normal R10 medium.  
3.2.3.7 Retroviral transduction of primary mouse B cells 
For the infection of 1-5 x 106 LPS-stimulated splenic mouse B cells, concentrated viral 
supernatant from five 6-cm PlatE-seeded dishes, previously transfected with plasmid of 
interest by lipofection, was used. Viral supernatant was collected in 2 mL Eppendorf tubes 
3 Materials and Methods 
49 
and centrifuged in a table top centrifuge at 20 000 g, 4 °C for 90 min. Following 
centrifugation, 1.25 mL of the supernatant was discarded and the remaining 0.75 mL was 
used to resuspend the viral pellet. LPS-stimulated mouse B cells were harvested in a 50 
mL Falcon tube and resuspended in the concentrated viral supernatant. LPS and 
Polybrene were added to the final concentrations of 20 μg/ml and 3 μg/ml, respectively. 
The cells were subsequently centrifuged with the viral supernatant at 1500 g at 33 °C for 
3.5 hours. The supernatant was discarded and the cells were resuspended in pre-warmed 
R10 medium supplemented with 20 μg/ml LPS, at a density of 1 x 106 cells/mL.   
3.2.3.8 Analysis of Ca2+ flux by flow cytometry 
In order to monitor BCR-induced Ca2+ mobilization by flow cytometry, the Ca2+ sensitive 
dye, polycyclic chelator Indo-1, was used. In its free, Ca2+-unbound form, Indo-1 emits 
fluorescence at 475 nm; while in the Ca2+-bound form its emission shifts to 400 nm 
(Grynkiewicz et al., 1985). The ratio of Indo-1 fluorescence at 405 nm to that at 530 nm 
was used to monitor the changes in intracellular Ca2+ concentration. 1.5 x 106 cells were 
harvested, resuspended in 700 μL RPMI medium with 5% FCS, and transferred to dark-
brown Eppendorf tubes. Indo-1 and pluronic acid were added onto the cells to the final 
concentrations of 1 μM and 0.015% (v/v), respectively. The cells were vortexed briefly and  
incubated at 30 °C for 25 min while shaking. Subsequently, 700 μL R10 medium was 
added and the cells were incubated at 37 °C for 10 min. The cells were washed twice with 
Krebs-Ringer buffer supplemented with 1 μM CaCl2. The cells were subsequently 
resuspended in 800 μL Ca2+-containing Krebs-Ringer buffer, and incubated at RT for 10 
min prior to the measurement. Ca2+ flux measurements were done with the BD LSRII flow 
cytometer. The ratio of fluorescence at 530 and 405 nm was monitored for 4 min. 30 sec 
after the start of recording, the stimulating antibody was added. DT40 cells were 
stimulated with 2 μg/ml α-chicken IgM (M4), DG75 cells were stimulated with 20 μg/ml α-
human IgM Fab fragment and mouse primary B cells were stimulated with 20 μg/ml α-
mouse IgM+IgG Fab fragments. The Ca2+ mobilization profiles were analyzed with the 
FlowJo software.   
3.2.3.9 Confocal laser scanning microscopy (CLSM) 
CLSM was used to analyze the subcellular localization and plasma membrane-recruitment 
of Citrine-tagged SLP65 variants. 5 x 105 cells were harvested, washed 2 times with 
Krebs-Ringer buffer and resuspended in 400 μL Ca2+-containing Krebs-Ringer buffer. The 
cells were transferred to 4-well imaging chambers or polylysine-coated imaging dishes 
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(used for primary mouse B cells) and allowed to settle down. The cells were imaged with 
the Leica TCS SP2 confocal laser scanning microscope in the department of Medical 
Microbiology (microscope kindly provided by Prof. Dr. Carsten Lüder). Citrine was excited 
at 514 nm and the emission was recorded at 530 – 600 nm. The cells were stimulated 
with 2 μg/ml α-chicken IgM M4 (DT40 cells), 20 μg/ml α-human IgM Fab fragment (DG75 
cells) or 20 μg/ml α-mouse IgM+IgG Fab fragment (mouse primary B cells). Images were 
processed and analyzed with the ImageJ software.  
3.2.3.10 Colocalization analysis of fluorescence signals 
For the colocalization analysis of SLP65 with quinacrine, 5 x 105 cells were harvested, 
washed once with Krebs-Ringer solution and stained with 1 μM quinacrine for 30 min at 
37 °C. Following staining, the cells were washed once with Ca2+-containing Krebs-Ringer 
buffer and transferred to imaging chambers. Cerulean (quinacrine) was excited at 458 nm 
and the emission was recorded at 470 - 500 nm. In order to avoid spectral overlap, Citrine 
and Cerulean signals were scanned sequentially. Z-stacks of 8 images were taken for 
each fluorophore. Background substraction (Rolling-ball radius 10.0 pixels), Gauss 
filtering and colocalization analysis were applied with the ImageJ software. 
3.2.3.11 Fluorescence recovery after photobleaching (FRAP) analysis 
For FRAP analysis, 5 x 105 cells were harvested, washed twice with Krebs-Ringer buffer 
and plated on imaging dishes. The cells were imaged with a Zeiss LSM 510 confocal laser 
scanning microscope in the Institute of Neuro- and Sensory Physiology (microscope kindly 
provided by Dr. M. Niebert). Time laps series of 25 images were taken. 5 pre-bleach 
images were taken, then a region of interest (ROI) was chosen and photo-bleached using 
maximum laser power, and subsequently 20 post-bleach images were acquired to monitor 
fluorescence recovery. Quantification of fluorescence in the ROI of individual images at 25 
time points was performed using the ImageJ software. Background subtraction and 
correction for fluorescence loss due to photobleaching was done. 
3.2.4 Biophysical methods 
3.2.4.1 Dynamic light scattering (DLS) 
DLS was used to monitor the size distribution of liposomes. The liposomes were prepared 
by extrusion and detergent exclusion methods as described above, and were diluted 1:20 
with LEW buffer prior to DLS analysis. DLS was performed with a DynaPro-MSXTC 
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instrument (Wyatt technology) in the department of Neurobiology, Max-Planck Institute for 
Biophysical Chemistry. 10 measurements per sample with an acquisition time of 10 sec 
were performed at 25 °C. The laser power was adjusted to keep the intensity between 
100000 and 2000000 counts. The results were processed with the DYNAMICS V6 
software (Wyatt technology) and analyzed with the OriginPro 8.5G software.  
3.2.4.2 Circular dichroism spectroscopy 
Circular dichroism was used to analyze the secondary structure of SLP655-50 in the 
absence and presence of SUVs. The lyophilized sample of SLP655-50 was prepared and 
kindly provided by C. Schwiegk (department of NMR-based Structural Biology, Max-
Planck Institute for Biophysical Chemistry). The protein was reconstituted in CD buffer to a 
final concentration of 50 μM. SUVs, prepared by the method of sonication and extrusion, 
were used at a total lipid concentration of 0.5-2 mM. The SUVs were incubated with the 
protein in a CD cuvette for 15 min at RT prior to the measurement. Chirascan Circular 
Dichroism Spectrometer (Applied Photophysics) and Hellma quartz cuvettes (pathlength 
0.1 cm) at the department of Neurobiology, Max Planck Institute for Biophysical Chemistry 
were used. The CD spectrum was recorded at 190 to 260 nm, with a step size of 1 nm, a 
bandwidth of 0.5 nm and an averaging time of 3 sec at RT. For baseline correction, the 
CD spectrum of the buffer was subtracted from the CD spectrum of the protein, and CD 
spectrum of SUVs was subtracted from the spectrum of the protein + SUVs. CD data was 
analyzed with the manufacturer’s ProView software and the DichroWeb online CD data 






4.1 NMR analysis of the secondary structure of SLP65 and validation of the 
structural investigations in vivo 
4.1.1 SLP65 possesses large intrinsically disordered regions 
The elucidation of the secondary and tertiary structure of a protein can help to understand 
many aspects of its function. We investigated the secondary structure of SLP65 by NMR 
in collaboration with the research group of Prof. Christian Griesinger at the department of 
NMR-based structural biology, Max-Planck Institute for Biophysical Chemistry. 
Recombinant 15N-1H labelled SLP65 was expressed in and purified from E.coli. In addition 
to full length SLP65, we used a shortened construct comprising the residues 40 to 330 of 
human SLP65. In this construct, the parts corresponding to the N-terminal positively 
charged region and to the SH2 domain were removed in order to improve the solubility of 
the protein and to facilitate the residue assignment. HSQC (heteronuclear single quantum 
coherence) spectra of both constructs at 298 K were recorded. Examination of the spectra 
revealed that SLP65 was largely intrinsically disordered as evident from the low peak 
dispersion (Figure 4.1).  
This result was in concert with the SLP65 structure prediction by the secondary structure 
prediction tools (prediction by the I-TASSER server;(Zhang, 2008). The spectra of full-
length SLP65 and SLP6540-330 could be overlaid, indicating that removing the N terminus 
and the SH2 domain did not interfere with the overall structure of SLP65. Moreover, the 
IDP (intrinsically disordered protein) character of SLP65 did not change upon in vitro 






Figure 4.1 SLP65 is an IDP except for the SH2 domain. 
15N-1H HSQC spectra of full-length human SLP65 (blue) and SLP6540-330 (red) are shown. Low 
peak dispersion indicates intrinsically disordered conformation. The proteins were cloned and 
purified by C. Schwiegk. The spectra were acquired and analysed by Dr. L. Russo.  
 
4.1.2 Intrinsic disorder in SLP65 is sufficient for the assembly of the Ca2+ initiation 
complex, but not for membrane targeting of SLP65 
The central part of SLP65 contains critical signalling elements – the inducibly 
phosphorylated tyrosine residues and the proline-rich regions. The NMR analysis showed 
that this part of SLP65 is disordered in solution. I wondered how the IDP character of 
SLP65 supports its function in vivo. I hypothesized that one could replace the IDP part of 
SLP65 by another disordered sequence and preserve the signalling function of the 
protein. To test this hypothesis, I generated a protein construct where the residues 50 to 
330 of human SLP65 were replaced by a flexible GS (Glycine Serine)-linker. The tyrosine 
residues that bind Btk and PLCγ2 were preserved in this construct, including a few amino 
acids upstream and downstream to allow for the recognition by the Syk kinase and the Btk 
and PLCγ2 SH2 domains. This synthetic protein construct was named “SLP65 GS”, and 
its full amino acid sequence is shown in Figure 4.2. It was expressed in SLP65-deficient 
DT40 cells and assessed for its ability to reconstitute Ca2+ signaling.  





Figure 4.2 Amino acid sequence of SLP65 GS.  
The residues in blue correspond to the N-terminal membrane targeting region and to the SH2 
domain. The tyrosine residues binding the SH2 domains of Btk and PLCγ2 are shown in red. The 
cDNA encoding for this synthetic protein was synthesized in parts by MWG operons, amplified via 
overlap extension PCR and cloned into the pMSCVpuro vector with an N-terminal Citrine-tag. 
 
Confocal laser scanning microscopy (CLSM)-imaging analysis revealed that Citrine-
tagged SLP65 GS was localized entirely in the cytosol of resting and BCR-stimulated 
cells. As it was not recruited to the plasma membrane, it is unsurprising that it failed to 
initiate Ca2+ mobilization upon BCR stimulation (Figure 4.3 B and C). Since SLP65 GS 
lacked the CIN85-binding sites (proline rich regions), and the interaction of SLP65 and 
CIN85 is critical for SLP65 membrane translocation (Oellerich et al., 2011), the signaling 
insufficiency of SLP65 GS could be attributed to the lack of CIN85 binding. To test for this 
possibility, I equipped the synthetic GS construct with the CIN85 predicted coiled-coil (CC) 
domain. The CIN85 CC domain has been previously shown in our lab to target SLP65 to 
the plasma membrane upon BCR stimulation, independently of the proline-rich regions 
(unpublished data by J. Kühn). The CC-SLP65 M23 or CC-SLP65 GS chimeric proteins 
were expressed in slp65-/- DT40 cells. Whereas the CIN85 CC domain provided signaling 
capability to the otherwise unfunctional ΔN SLP65 M23, it failed to do so when fused to 
the GS construct (Figure 4.3 B). This result suggested that the mere absence of CIN85 
binding is not sufficient to account for the severe Ca2+ phenotype of the synthetic SLP65 
GS construct. It therefore remains unclear why SLP65 GS and CC-ΔN GS were unable to 
translocate to the plasma membrane upon BCR ligation, even though all known domains 
required for membrane targeting of SLP65 were present. This data implies that the central 
disordered part of SLP65 contains a previously unrecognized membrane targeting site. It 
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might mediate the membrane anchoring of SLP65 via an interaction with an unknown 
protein ligand or contribute in a structural manner. It could also support the function of the 
already known membrane targeting domains, such as the SH2 domain or the N terminus 




Figure 4.3 The central part of SLP65 is indispensable for membrane targeting. 
A) Schematic representation of the domain organization of SLP65 WT, GS, CC-ΔN M23 and CC-
ΔN GS. B) The constructs represented in (A) with an N-terminal Citrine tag (not shown) were 
retrovirally transduced into slp65-/- DT40 cells. Ca2+ mobilization was measured by flow cytometry. 
The Ca2+ flux profiles of cells with equal Citrine expression are shown. C) Subcellular localization 
and plasma membrane recruitment of Citrine-tagged SLP65 WT, GS and CC-ΔN was analysed by 
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Due to these numerous possibilities, it is not surprising that the very complex and delicate 
process of membrane targeting of SLP65 was inhibited by the introduction of the 
disordered GS sequence. However, the data presented until now did not exclude the 
possibility that the intrinsic disorder in SLP65 is useful later for the assembly of the Ca2+ 
initiation complex; which is a distinct process downstream of plasma membrane 
recruitment of SLP65. To test whether this was the case, I fused a known BCR-targeting 
signal, the tandem SH2 domains of Syk kinase, at the C-terminus of SLP65 GS and 
thereby “bypassed” the natural membrane targeting step (Figure 4.4 A). The tandem SH2 
domains of Syk bind to phosphorylated tyrosine residues at the ITAMs of Igα and Igβ with 
high affinity (Kurosaki et al., 1995; Ottinger et al., 1998). Covalently joining these domains 
to SLP65 has been shown to bring it to the BCR upon stimulation (Bremes, 2012). 
As shown in Figure 4.4 C, SLP65 GS t(SH2)2 efficiently translocated to the plasma 
membrane upon BCR ligation. Moreover, this chimeric protein could initiate Ca2+ signaling 
(Figure 4.4 B). This indicated that even though the GS-linker could not replace the original 
SLP65 sequence for membrane targeting, it was sufficient for the assembly of the Ca2+ 
initiation complex and Ca2+ mobilization after SLP65 was brought to the BCR. Finally, by 
omitting the N-terminal region of SLP65, I created a minimal protein construct that could 
fulfill the function of SLP65 for Ca2+ signaling. It consisted of a flexible GS-rich scaffold, 
including the important tyrosine residues, and a BCR-targeting signal, the tandem SH2 
domains of Syk. This chimeric protein, termed ΔN SLP65 GS t(SH2)2 could support Ca2+ 
mobilization upon BCR-stimulation (Figure 4.4 B). Moreover, immunoblot analysis with 
phospho-specific antibodies revealed that ΔN SLP65 GS t(SH2)2 was efficiently tyrosine-
phosphorylated. It remained phosphorylated even 5 minutes after IgM stimulation, in 
comparison to SLP65 WT, which reached its maximum level of phosphorylation 2 minutes 
after BCR stimulation and showed reduced phosphorylation 5 minutes after activation 
(Figure 4.4 D, lanes 1-6). This was consistent with the stable association of ΔN SLP65 GS 
t(SH2)2 with the plasma membrane 5 min after BCR stimulation (data not shown). Lysates 
from cells expressing the SLP65 variant YallF, where 5 tyrosine residues known to be 
phosphorylated by Syk were exchanged against phenylalanine (kindly provided by Dr. M. 
Engelke), were used as a negative control. In this case, no phosphorylation of SLP65 






Figure 4.4 The GS linker in the central part of SLP65 is sufficient for Ca2+ signaling once 
SLP65 is brought to the BCR. 
A) Schematic representation of the domain structure of SLP65 WT, GS, GS t(SH2)2 and ΔN GS 
t(SH2)2. B) The constructs represented in (A) with an N-terminal Citrine tag (not shown) were 
retrovirally transduced into slp65-/- DT40 cells and Ca2+ mobilization was measured by flow 
cytometry. The Ca2+ flux profiles of cells with equal Citrine expression are shown. C) Plasma 
membrane recruitment of SLP65 WT or GS t(SH2)2 upon BCR-stimulation was analyzed by CLSM. 
Images were taken before and 3 min after stimulation with 2 µg/ml α-chicken IgM antibody. D) 
CCLs were prepared from resting and stimulated DT40 cells expressing either SLP65 WT, ΔN GS 
t(SH2)2 or YallF variants and analyzed for tyrosine-phosphorylation of SLP65 by immunoblotting 
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The data presented until now shows that the lack of secondary structure in the central part 
of SLP65 is compatible with the assembly of the Ca2+ initiation complex. However, this 
part contains a membrane targeting site, and therefore might not adopt the disordered 
conformation at all times during SLP65 activation. It is possible that an ordered 
conformation of this region of the protein exists and is necessary for the membrane 
anchoring process of SLP65. 
4.1.3 Btk and PLCγ2 assemble on SLP65 in a spatially defined manner 
The results presented until now have indicated that the central part of SLP65 between 
residues 40 and 330 is disordered and can be functionally substituted by a GS-linker 
under certain conditions. To investigate the flexibility of SLP65 in living cells further, I 
created another synthetic protein construct, a variant of SLP65 where the Btk and PLCγ2 
binding sites were swapped. I hypothesized that, given the disordered nature of the 
central part, the signaling function of this variant would not be affected. Human SLP65 
interacts with the Btk SH2 domain via the residue pY96, and with PLCγ2 C2 and tandem 
SH2 domains via residues pY119, pY178 and pY189, respectively (Chiu et al., 2002; 
Engelke et al., 2013). I generated a construct where the original Btk-binding site was 
inactivated by an amino acid substitution to phenylalanine (Y96F) and a new Btk-binding 
site was introduced downstream of the PLCγ2-binding sites. The tyrosine residues, 
mediating the interaction of SLP65 with Btk and PLCγ2, are represented in Figure 4.5 in 
the context of WT SLP65, and in the new construct SLP65 Y96FnewBtk. 
Slp65-/- DT40 cells were retrovirally transduced with either SLP65 WT or Y96FnewBtk. 
The cells expressing the Y96FnewBtk variant did not respond to BCR stimulation with 
Ca2+ mobilization, even though the protein was recruited to the plasma membrane (Figure 
4.6 A and B). The inability of SLP65 Y96FnewBtk to mount an adequate Ca2+ response 
could be explained by insufficient tyrosine phosphorylation by Syk and/or by poor 






Figure 4.5 Schematic representations of the Btk- and PLCγ2-binding sites on SLP65 and the 
synthetic construct SLP65 Y96FnewBtk.  
In the Y96FnewBtk construct the original Btk-binding site was inactivated by a point mutation Y96F 
and a new Btk-binding site was generated at position 227. The newly introduced Btk-binding site 
contained the complete phosphotyrosine motif, including a few amino acids upstream and 
downstream the tyrosine residues to ensure efficient phosphorylation by Syk and recognition by the 
Btk SH2 domain. The cDNA encoding SLP65 Y96FnewBtk was synthesized by MWG operons and 
cloned into the pMSCVpuro vector with an N-terminal Citrine-tag. 
  
In order to test the functionality of the new Btk-binding site, I performed pull down 
experiments with the GST-Itk SH2 domain fusion protein. This GST-fusion protein was 
used to pull down SLP65 from lysates of resting and BCR-stimulated cells, expressing 
either SLP65 WT or Y96newBtk. The SH2 domain of Itk interacts with the 
phosphotyrosine motif in SLP76, the functional homologue of SLP65. The motif 
recognized by Itk is identical to that recognized by the Btk SH2 domain (YEPP). The Itk 
SH2 domain was used instead of the Btk SH2 domain due to technical difficulties 
encountered while purifying the GST-Btk SH2 domain fusion protein. As seen in Figure 
4.6 C, both SLP65 WT and Y96FnewBtk were efficiently precipitated with the GST-Itk SH2 
domain, but not with the GST-only control, from the lysates of BCR-stimulated cells (lanes 
5, 6 and 14, 15, respectively). Moreover, application of phospho-specific antibodies to the 
immunoblot containing precipitated SLP65 revealed that both variants were efficiently 
tyrosine phosphorylated upon BCR-stimulation. These data demonstrated that the SLP65 
Y96FnewBtk variant was recruited to the plasma membrane and the newly introduced 



















Figure 4.6 Swapping Btk and PLCγ2 binding sites in SLP65 renders it unfunctional. 
A) DT40 slp65-/- cells were reconstituted with Citrine-tagged SLP65 WT or Y96FnewBtk and 
analyzed for Ca2+ mobilization by flow cytometry. The Ca2+ flux profiles of cells with equal Citrine 
expression are shown. B) Subcellular localization and plasma membrane recruitment of Citrine-
tagged SLP65 variants was analyzed by CLSM. Images before and 3 min after stimulation with 2 
µg/ml α-chicken IgM antibody are shown. C) The GST-Itk SH2 domain was expressed and purified 
from E.coli. It was used to precipitate SLP65 from lysates of resting and BCR-stimulated slp65-/- 
DT40 cells reconstituted with either SLP65 WT or Y96FnewBtk. A pull down experiment with GST-
only protein was performed as a control, to exclude unspecific binding of SLP65 to the GST-tag. D) 
Citrine-taged SLP65 was immunoprecipitated with an α-GFP antibody from CCLs of resting and 
BCR-stimulated DT40 cells, expressing either SLP65 WT or Y96FnewBtk. An immunoblot for 
PLCγ2 was performed to detect the association with SLP65.  
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The compromised Ca2+ mobilization profile of the Y96FnewBtk variant could still be 
explained by the inability of this construct to bind PLCγ2, since the spacing of the Btk- and 
PLCγ2-binding sites was altered. I therefore performed a co-immunoprecipitation 
experiment, where Citrine-tagged SLP65 WT or Y96FnewBtk was precipitated from the 
cellular lysates with an α-GFP antibody, and an immunoblot for PLCγ2 was performed to 
detect its association with SLP65. PLCγ2 could only be co-immunoprecipitated with 
SLP65 WT from cells stimulated via their BCR for 2 min, but not with SLP65 Y96FnewBtk, 
indicating that the Y96FnewBtk variant of SLP65 indeed cannot bind PLCγ2 (Figure 4.6 D, 
lanes 2 and 4-6). This can be explained by the close proximity of the PLCγ2- and the new 
Btk-binding sites, which doesn’t allow for simultaneous binding of Btk and PLCγ2. This 
can in turn account for the weak Ca2+ response, since Btk and PLCγ2 need to tether to a 
single SLP65 molecule in order for phosphorylation and activation of PLCγ2 to take place.  
In summary, these results indicate that the spacing and the orientation of the Btk- and 
PLCγ2- binding sites on SLP65 are important for the assembly of an active Ca2+ initiation 
complex. The intrinsic disorder in SLP65 is tolerated, or maybe even advantageous for the 
binding of Btk and PLCγ2, but the two enzymes have to be positioned on SLP65 in a 
defined manner.  
 
4.2 Structural and functional analysis of the N-terminal region of SLP65 
4.2.1 Evaluation of previous studies on the SLP65 N terminus 
We omitted the N-terminal region of SLP65 for the investigation of SLP65 structure by 
NMR due to technical reasons (low solubility of the full-length construct). However, the N 
terminus of SL65 is critical for SLP65 activation and membrane targeting, and the 
respective mechanism is unknown. I therefore studied the structure and function of this 
enigmatic part of SLP65.  
To analyze the function of the SLP65 N terminus, I reconstituted the slp65-/- DT40 cell line 
with SLP65 variants harboring single point mutations or deletions in this region. The 
essential N-terminal part of SLP65 can be defined as the first 50 amino acids since the 
mutant variant lacking these 50 amino acids, SLP65 ΔN, is able to elicit only a very weak 





Figure 4.7 The N-terminal region of SLP65 is critical for its function. 
A) Schematic representation of SLP65 WT and ΔN. B) slp65-/- DT40 cells were reconstituted with 
SLP65 WT or ΔN and Ca2+ mobilization was monitored by flow cytometry. The Ca2+ flux profiles of 
cells with equal Citrine expression are shown. C) Plasma membrane recruitment of SLP65 WT or 
ΔN upon BCR-stimulation was analyzed by CLSM. Images before and 3 min after stimulation with 
2 µg/ml α-chicken IgM antibody are shown. 
 
The N-terminal region of SLP65 is highly conserved among species. Bioinformatic 
analysis of the amino acid sequence of this region reveals several potential motifs for 
interaction with other proteins. One of these motifs is a predicted Calmodulin-binding site. 
Calmodulin (CaM) is the key regulator of Ca2+ signaling in many cell types. It binds its 
targets with a protein domain known as “EF hands”, which recognizes bulky hydrophobic 
amino acids such as W, F, I, L or V, with a certain spacing (reviewed by(Chin & Means, 
2000). SLP65 has one classical CaM-binding motif of type 1-5-10 at positions 31 to 41, 
and two further possible motifs of type 1-8-14 where the last amino acid is shifted by one 
position (shown in Figure 4.8 A). The potential interaction between SLP65 and CaM has 
been investigated by N. Herrmann in our lab, who found that this interaction can be 
detected in vitro by means of pull down assays employing CaM-agarose and the isolated 
N terminus of SLP65 (Herrmann, 2009). I attempted to verify this interaction in vivo. I 
cloned the chicken CaM cDNA and expressed the Citrine-tagged CaM in DT40 WT cells. 









































cells. I also monitored CaM localization 1, 3 and 5 min after cell stimulation with α-IgM 
antibodies. Interestingly, the localization of CaM did not change upon BCR stimulation 
(Figure 4.8 B). Nor did the overexpression of CaM in DT40 cells influence the Ca2+ flux 
upon BCR ligation (Figure 4.8 C).  
 
Figure 4.8 The putative SLP65-Calmodulin interaction cannot be observed in vivo and the 
overexpression of CaM does not affect BCR-induced Ca2+ mobilization.  
A) Amino acid sequence of human, mouse and chicken SLP65 with the putative CaM-binding sites 
in the N terminus as predicted by the Calmodulin Target Database. B) DT40 WT cells were 
retrovirally transduced with Citrine-tagged chicken CaM and the localization of CaM was monitored 
by CLSM. Images before and 1, 3 or 5 min after stimulation with 2 µg/ml α-chicken IgM antibody 
are shown. C) Intracellular Ca2+ flux was monitored by flow cytometry in DT40 WT cells and DT40 
WT cells transduced with Citrine-CaM. D) DT40 slp65-/- cells, previously transfected with OS-
SLP65, were retrovirally transduced with either Citrine only or Citrine-tagged CaM. CCLs were 
prepared from resting and BCR-stimulated cells and subjected to immunoprecipitation with 2 μg α-
GFP antibody. Immunoblot with α-SLP65 and α-Calcineurin antibodies was performed to detect the 
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Finally, I performed a protein immunoprecipitation experiment and pulled down Citrine-
CaM with the help of an α-GFP antibody.  An immunoblot for SLP65 was subsequently 
performed in order to detect a potential interaction between the two proteins. I used DT40 
slp65-/- cells reconstituted with human One-Strep tagged SLP65 and additionally 
transfected with Citrine-CaM or Citrine only (in order to exclude unspecific binding of 
proteins to the Citrine tag). As can be seen in Figure 4.8 D, SLP65 could not be co-
immunoprecipitated with CaM (lanes 3-4) from the lysates of resting or stimulated cells. 
However, a known interaction partner of CaM, Calcineurin, was successfully co-
immunoprecipitated (Figure 4.8 D, lanes 3-4), indicating that the pull down has worked, 
and that the Cit-CaM fusion protein is functional and can bind its ligands. The lysis buffer 
used in this experiment contained 10 μM CaCl2 corresponding to a sufficiently high 
concentration of Ca2+ to ensure that CaM is able to interact with its targets.  
In conclusion, the interaction of SLP65 with CaM could not be detected in living cells. 
Moreover, overexpression of CaM did not have a positive or negative regulatory effect on 
early BCR signaling indicating that the potential interaction of CaM with the SLP65 N 
terminus doesn’t play a major role for the activation and membrane recruitment of SLP65. 
Another motif proposed to exist in the SLP65 N terminus, is the so called “leucine-zipper” 
motif, as suggested by Koehler et al. The arrangement of hydrophobic amino acids in this 
region indeed reminds a classical heptad repeat pattern characteristic of leucine zippers 
(Figure 4.9 A), where the positions a and d are occupied by hydrophobic, and positions e 
and g by charged residues. In the study from Koehler et al, a substitution of the isoleucine 
residue central to the leucine zipper motif with a glutamate residue (I25E) was shown to 
abolish the membrane localization and function of SLP65 (Kohler et al., 2005). I25E is a 
drastic amino acid substitution from a biochemical point of view, since glutamate (E) has a 
hydrophilic and negatively charged side chain which could distort the contrasting 
hydrophobic and positively charged environment created by other residues of the SLP65 
N terminus. I therefore expressed additional point mutants of SLP65, I25K and I25A, in 
DT40 slp65-/- cells and analyzed their subcellular localization and Ca2+ mobilization 
profiles. I used substitutions to alanine or lysine in order to preserve the hydrophobic 
nature or the overall positive charge of the N terminus, respectively. As shown in Figure 
4.9 B and C, the Ca2+ mobilization of these mutants was only marginally impaired and the 
plasma membrane recruitment of SLP65 upon BCR stimulation was readily observed. 
Thus, inactivation of the predicted leucine zipper via amino acid substitutions for other 





Figure 4.9 Single amino acid exchanges in the putative leucine zipper motif of SLP65 
differentially affect BCR-induced Ca2+ mobilization.  
A) Amino acid sequence of human, mouse and chicken SLP65, and the putative leucine zipper 
motif the N-terminal region are shown. B) and D) DT40 slp65-/- cells were retrovirally transduced 
with constructs encoding Citrine-tagged SLP65 WT, I25A, I25K, L18K or L18A and Ca2+ 
mobilization was monitored by flow cytometry. The Ca2+ flux profiles of cells with equal Citrine 
expression are shown. C) and E) Subcellular localization and plasma membrane recruitment of 
Citrine-tagged SLP65 I25K and L18K was analyzed by CLSM. Images before and 3 min after 
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I extended the mutational analysis to another hydrophobic residue in the SLP65 N 
terminus – L18. In this case, substitution of L18 to A or K strongly reduced the BCR-
induced Ca2+ mobilization (Figure 4.9 D). Moreover, the plasma membrane recruitment of 
SLP65 L18A and L18K could not be detected (Figure 4.9 E). L18 is therefore, in contrast 
to I25, indispensable for the membrane targeting of SLP65.  
To conclude, my data excludes a functional leucine zipper motif in the N terminus of 
SLP65. Besides, previous studies from our lab elucidated the interactome of SLP65 in 
resting and stimulated B cells by quantitative mass spectrometry. In this study more than 
30 binding partners of SLP65 were identified, however no ligand for the putative leucine 
zipper motif was found (Oellerich et al., 2011). The dependence of SLP65 function on 
L18, however, could point to a general requirement for hydrophobic residues in the SLP65 
N terminus. 
4.2.2 The N terminus of SLP65 is a novel lipid-binding module which targets 
SLP65 to vesicles in resting B cells 
To further investigate the function of the N terminus in membrane targeting of SLP65, we 
used CLSM imaging and cell fractionation experiments and analyzed SLP65 distribution in 
living cells. Dr. M. Engelke has observed that Citrine-tagged WT SLP65 is localized in the 
cytosol as well as in intracellular dot-like structures of resting DT40 cells. Interestingly, 
these dots disappeared shortly after BCR stimulation, which coincided with the 
appearance of SLP65 at the plasma membrane. He performed a series of colocalization 
experiments employing Citrine-tagged SLP65 and Cerulean-tagged vesicular markers 
which were co-expressed in the same cell. His analysis revealed that SLP65 colocalizes 
with the exosomal vesicular markers quinacrine and Vamp7 (vesicle-associated 
membrane protein 7) in resting DT40 cells. In contrast, no colocalization of SLP65 with 
Golgi or endosomal markers was observed. Colocalization with quinacrine and Vamp7 
depended on the N-terminal region of the protein (Engelke et al., 2014)and Figure 4.10 A).  
In order to confirm the membrane association of SLP65 in resting cells, cellular 
fractionation assays were performed by J. Kühn. In these experiments, DT40 slp65-/- cells 
reconstituted with either WT or N-terminal variants of SLP65 ΔN or L18K were lysed by 
the nitrogen cavitation method in a hypotonic buffer without any detergent in order to 
preserve the intracellular membranes. The lysates were then fractionated on a sucrose 
gradient. Fractions were taken for analysis and the SLP65 distribution in the sucrose 
gradient was analyzed by immunoblotting. As shown in Figure 4.10 B, WT SLP65 was 
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largely found in the cytosolic fractions. However some SLP65 was also present in the 
interphase between fractions containing 35% and 45% sucrose, corresponding to a 
compartment containing membranes of high density. In contrast, the signaling 
incompetent mutants of SLP65, ΔN and L18K, were found exclusively in the cytosolic 




Figure 4.10 SLP65 colocalizes with vesicular markers quinacrine and Vamp7 dependent on 
its N terminus.  
A) DT40 slp65-/- cells were retrovirally transduced with Citrine-tagged SLP65 and Cerulean-tagged 
vesicular markers. Colocalization of SLP65 WT with Vamp7 and quinacrine was assessed by 
CLSM and is indicated by white dots in the “colocalization” panel. Imaging and colocalization 
analysis was performed by Dr. M. Engelke. B) DT40 slp65-/- cells reconstituted with SLP65 WT, ΔN 
or L18K were lysed by the nitrogen cavitation method and subjected to subcellular fractionation on 
a discontinuous sucrose gradient by ultracentrifugation. SLP65 distribution in cytosolic and 
membrane fractions was analyzed by immunoblotting. Immunoblot for the cytosolic protein Akt1 
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Collectively, these data indicate that SLP65 associates with vesicular membranes in 
resting B cells dependent on its N terminus. This finding is in accordance with the data by 
Koehler et al, who also detected a basal level of membrane association of SLP65 in 
resting B cells and when ectopically expressed in other cell types, even though plasma 
membrane and not vesicular localization was reported (Kohler et al., 2005).  
The imaging and cell fractionation experiments have indicated that two pools of SLP65 
exist in resting DT40 cells – the cytosolic pool and the vesicular pool. I wondered whether 
there is a clear separation between these two pools or whether protein exchange can take 
place between the cytosol and vesicles. I therefore analyzed the mobility of SLP65 in vivo 
with a Fluorescence Recovery after Photobleaching (FRAP) assay. For these 
experiments, DT40 slp65-/- cells reconstituted with Citrine-tagged SLP65 were used. First, 
a series of images of a single cell was taken. Subsequently, a region of interest 
encompassing one bright dot/speckle, presumably corresponding to vesicle-associated 
SLP65, was chosen. Next, this region was photo-bleached with a strong laser pulse. 
Immediately after the bleach-pulse a series of post-bleach images was taken in order to 
monitor the fluorescence recovery in real time. In FRAP experiments, slow and incomplete 
fluorescence recovery indicates the presence of a large immobile fraction of the 
fluorophore – in this case, Citrine-SLP65. This would mean SLP65 is stably associated 
with the vesicle and therefore unable to exchange with the cytosol. Fast and complete 
fluorescence recovery, on the other hand, implies absence of an immobile fraction and 
free diffusion of SLP65 between the cytosolic and vesicular pools.  
As can be seen in Figure 4.11, rapid fluorescence recovery of Citrine-SLP65 was 
observed, indicating that there’s a steady exchange between the cytosolic and the 
membrane-associated fractions. For comparison, I photo-bleached Cerulean-tagged 
Vamp7 expressed in DT40 WT cells and monitored its fluorescence recovery. 







Figure 4.11 Cytosolic and membrane fractions of SLP65 are in constant exchange. 
A) FRAP was monitored in DT40 slp65-/- cells reconstituted with human Citrine-SLP65 (upper 
panel) or DT40 WT cells transduced with Cerulean-Vamp7. The region of interest, chosen for 
photo-bleaching, is indicated by white arrows. 5 images were taken before, and 20 images after the 
photobleaching. B) Quantification of fluorescence in the region of interest before and after the 
bleach pulse is shown. n=7, ± SD (standard deviation). 
 
Our data showed that the N terminus mediates reversible association of SLP65 with 
vesicles. I therefore asked the question: what is the molecular nature of this membrane 
association and what is the ligand for the SLP65 N terminus? Proteomic approaches, 
previously applied in the lab, did not identify a protein ligand for this part of SLP65 
(Oellerich et al., 2011). Therefore, I tested whether SLP65 could bind lipid components of 
intracellular membranes with a liposome floatation assay, established in the lab of K. 
Kühnel (Busse et al., 2013). In this method, unilamellar liposomes of the desired lipid 
composition are prepared and incubated with the recombinant protein of interest. 
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Subsequently, the protein-liposome mixture is overlaid with a Nycodenz gradient and 
subjected to ultracentrifugation. During ultracentrifugation the liposomes float up to the top 
of the gradient due to their low density. The protein stays at the bottom of the tube if it 
doesn’t bind to liposomes. If binding takes place, the protein also migrates up to the top of 
the tube (Figure 4.12 B). For this assay, N-terminally His6-tagged variants of SLP65, WT, 
ΔN and L18K, purified on Ni-NTA affinity chromatography columns were used (Figure 




Figure 4.12 The purification of His-tagged SLP65 and an overview of the liposome floatation 
method.  
A) His6-tagged human SLP65 variants were expressed in E.coli and purified on Ni-IDA columns. 
Two elution fractions were collected (E1 and E2) and 5 μL of the eluted protein was loaded on the 
gel together with a known amount of BSA standard for quantification. The gel was stained with 
Coomasie for protein visualization. B) Schematic representation of the liposome floatation method. 
The protein-liposome mixture is overlaid with a Nycodenz gradient and subjected to 

































Small unilamellar liposomes (SUVs) were prepared with the “detergent removal” 
technique.  Since previous work by N. Herrmann has indicated that the SLP65 N terminus 
could bind several PIP species (Herrmann, 2009), PIPs were included in the liposome 
composition. I therefore prepared liposomes consisting of 70% phosphatidylcholine (PC), 
23% phosphatidylethanolamine (PE), 5% PIP (either phosphatidyl inositol 3-phosphate, 
phosphatidyl inositol 4-phosphate or phosphatidyl inositol 5-phosphate) and 2% Texas-
Red (TR)-labeled PE, which was used as a tracer. As a control, liposomes not-containing 
any PIPs, and therefore consisting of only PC (75%) and PE (23% PE and 2% TR-PE) 
were prepared. 
As shown in Figure 4.13 A (left panel), WT SLP65 associated with the liposomes 
independent of lipid composition and was found in the topmost two fractions. SLP65 ΔN, 
in contrast, was only found in the lowermost fractions, indicating that it did not bind to the 
liposomes (Figure 4.13 A, right panel). This data showed that SLP65 can associate with 
neutral liposomes, composed of only PC and PE, dependent on its N terminus. Next, I 
tested the SLP65 variant L18K for binding to PC:PE liposomes. As shown in Figure 4.13 B 
(right panel), similarly to SLP65 ΔN, SLP65 L18K did not float with the liposomes. In order 
to exclude unspecific binding of SLP65 to TR, which is a fluorescent dye with a negative 
charge and could therefore bind to positively charged SLP65 via unspecific electrostatic 
interactions, I used liposomes containing Oregon-Green (OG)-labeled PE. WT SLP65 
bound equally well to both TR- and OG-labeled liposomes, while L18K did not associate 
with the liposomes independent of the dye type (Figure 4.13 B), indicating that liposome 
binding by SLP65 is specific. 
Altogether, these data show that the SLP65 N terminus is a lipid-binding motif which can 
mediate interaction of SLP65 with liposomes in vitro. Deletion of the N-terminal region or 
the single amino acid substitution of L18 to K abolished the interaction of SLP65 with 
SUVs. In vivo, the SLP65 mutants ΔN and L18K also do not associate with intracellular 
membranes as shown with the cell fractionation assays. Moreover, these variants of 
SLP65 are signaling incompetent, i.e. they cannot initiate Ca2+ signaling. Therefore I 







Figure 4.13 SLP65 binds to neutral liposomes dependent on its N terminus.  
A) Liposome floatation assay was performed with recombinant His6-tagged WT and ΔN and SUVs 
consisting of PC, PE and PIP; or PC and PE only. Representative immunoblots developed with an 
α-SLP65 antibody are shown. B) Liposomes of the same lipid composition, but with different 
fluorescent labels – either TR or OG were prepared. Liposome floatation assay was performed with 
WT and L18K SLP65 and SUVs labeled with either TR (upper panel) or OG (lower panel). 
Representative immunoblots, developed with an α-SLP65 antibody, are shown.  
 
4.2.3 The N terminus of SLP65 binds preferentially to negatively charged 
membranes and may recognize membrane curvature 
Next, I aimed at characterizing the newly identified interaction of the SLP65 N terminus 
with lipids. To study the specificity of lipid binding, I performed liposome floatation 
experiments with liposomes of different size and lipid composition. Since the SLP65 N 
terminus is rich in positively-charged amino acids, such as lysines and arginines, I 
hypothesized that it would preferentially bind to negatively charged membranes. I hence 
performed floatation assays with liposomes containing a negatively charged lipid 
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phosphatidylserine (PS) in their composition. In order to compare the affinities of SLP65 
for negatively charged versus neutral liposomes, I increased the amount of protein used in 
my floatation experiments. By using 5 times more protein, I could reach a condition where 
not all SLP65 was bound to PC:PE liposomes and some protein remained in the non-
liposomal fractions. I then performed the floatation experiment with the same protein:lipid 
molar ratio, but used negatively charged liposomes. As shown in Figure 4.14, at higher 
protein:lipid ratios (left panel) incomplete binding of SLP65 to neutral SUVs was observed, 
whereas almost all protein was bound to negatively charged SUVs. This experiment 
shows that SLP65 has a higher affinity for PS-containing liposomes, suggesting that the 
binding of the SLP65 N terminus to membranes is mediated, at least in part, by 
electrostatic interactions.  
 
 
Figure 4.14 SLP65 preferentially binds to negatively charged liposomes.  
A) Either 1 μL (left panel) or 5 μL (right panel) SLP65 was incubated with PC:PE (75:25) or 
PC:PE:PS (65:25:10) liposomes and a liposome floatation experiment was performed. 
Representative immunoblots, developed with an α-SLP65 antibody, are shown. B) Quantification of 
the band intensities in the top two fractions (liposome-bound) and lowermost four fractions (free 
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The membranes enclosing different organelles in a cell have a highly variable lipid 
composition, which gives them different physical and chemical properties. These different 
parameters, such as electrostatics, lipid packing and membrane curvature, are recognized 
by peripheral membrane proteins, which adhere to membranes from the cytosol (Bigay & 
Antonny, 2012). My data until now has indicated that SLP65 can recognize membranes 
based on their charge. Next, I asked the question whether it could also recognize 
membrane curvature.  
Therefore, in addition to SUVs, prepared by the “detergent removal” method, I also 
prepared Large Unilamellar Vesicles (LUVs) via the “extrusion” method. This method 
generates vesicles of a certain diameter by mechanically extruding a lipid suspension 
through a series of filters of different pore size. By extruding a suspension of multilamellar 
vesicles (MLVs) through 0.4 and 0.1 μm filters, I prepared liposomes of ~60 nm radius. 
The sizes of LUVs and SUVs were monitored by Dynamic Light Scattering (DLS). Both 
liposome preparations were homogenous in size and the average geometric radius was 
determined to be 18 nm for SUVs and 60 nm for LUVs (Figure 4.15 A). I then tested the 
affinity of SLP65 for these two types of vesicles by means of floatation assays. Prior to 
use in the floatation experiment, the concentration of the liposomes was adjusted by 
measuring the absorbance of TR at 590 nm and diluting the more concentrated vesicle 
suspension with the appropriate buffer. As shown previously, SLP65 readily bound to 
SUVs consisting of PC and PE. Interestingly, no binding of SLP65 to LUVs of the same 
lipid composition was observed (Figure 4.15 B and C). As a control, a floatation 
experiment with Hsv2, a protein which binds to liposomes independent of curvature, was 
performed. Hsv2 recognizes PI3P, therefore 5% of this lipid was included in the lipid 
composition of both SUVs and LUVs (Busse et al., 2013). Hsv2 associated with both 
SUVs and LUVs, indicating that both type of liposomes were intact, and are in principle 





Figure 4.15 SLP65 binds preferentially to small liposomes.  
A) Size distribution of SUVs and LUVs, both consisting of 75% PC and 25% PE, and prepared by 
detergent removal and extrusion methods, respectively, was measured by DLS. B) The liposome 
floatation assay was performed with His6-tagged SLP65 WT and PC:PE SUVs/LUVs. The liposome 
concentration was adjusted prior to incubation with the protein based on the absorbance of Texas-
Red at 590 nm. Representative immunoblots, developed with an α-SLP65 antibody, are shown. C) 
The quantification of band intensities in the uppermost two fractions (bound protein) vs. lowermost 
four fractions (free protein) is shown. n=3 ± SD. D) The liposome floatation experiment was 
performed with recombinant Hsv2, kindly provided by A. Scacioc, and 5% PI3P-containing 
SUVs/LUVs, in HP150 buffer, pH 7.4. The floatation experiment, employing liposomes of the same 
lipid composition, but prepared in LEW buffer, was performed with SLP65. Representative 
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Preferential binding of SLP65 to SUVs indicated that it can recognize membrane 
curvature. To test this hypothesis in vivo, I generated chimeric proteins where the N-
terminal region of SLP65 was substituted with known curvature sensitive lipid-binding 
domains. I chose two well-characterized curvature-recognition domains, the N-BAR (Bin-
Amphiphysin-Rvs) domain of Amphyphisin and the ALPS (Amphipatic Lipid Packing 
Sensor) motif of α-Synuclein. BAR domains are composed of oligomerized long α-helices 
which bind to curved membranes due to their crescent-shape. ALPS motifs are unfolded 
hydrophobic sequences, which adhere weakly to loosely packed membranes and fold into 
amphipatic α-helices on the membrane surface (reviewed by(Antonny, 2011). I cloned the 
cDNA for the mouse Amphiphysin BAR domain and the α-Synuclein ALPS motif and 
generated the chimeric constructs N-BAR-ΔN SLP65 and ALPS-ΔN SLP65, shown in 
Figure 4.16 A. These chimeras were expressed in DT40 slp65-/- cells and assessed for 
their ability to reconstitute Ca2+ signaling.  
As shown in Figure 4.16 B, the chimeric protein harboring the N-BAR domain of 
Amphiphysin (N-BAR-ΔN) could fully support BCR-induced Ca2+ mobilization. It was also 
distributed similarly to WT SLP65 – it localized in the intracellular dot-like structures in 
resting cells and at the plasma membrane in BCR-stimulated cells (Figure 4.16 C). 
Moreover, this chimeric protein was efficiently tyrosine-phosphorylated upon BCR 
stimulation as shown in Figure 4.16 D (lanes 6-9). The ALPS domain of α-synuclein, on 
the contrary, did not target SLP65 to intracellular vesicles, nor could it bring the protein to 
the plasma membrane (Figure 4.16 C). Therefore it is not surprising that the ALPS-ΔN 






Figure 4.16 The N terminus of SLP65 can be substituted by the N-BAR domain of 
Amphiphysin.  
A) Schematic representation of the chimeric SLP65 variants containing curvature-sensing lipid-
binding domains. B) The constructs represented in A were retrovirally transduced into slp65-/- DT40 
cells. Ca2+ mobilization was analyzed by flow cytometry. The Ca2+ flux profiles of cells with equal 
Citrine expression are shown. C) CLSM imaging analysis of Citrine-tagged SLP65 N-BAR and 
ALPS variants. Images taken before and 3 min after stimulation with 2 μg/ml α-chicken IgM are 
shown. D) CCLs were prepared from resting and BCR-stimulated cells expressing SLP65 WT, N-



























































I showed that curvature-sensitive N-BAR domain of Amphiphysin can substitute the 
SLP65 N terminus and support BCR signaling. This implies that this domain targeted 
SLP65 to vesicles similar to those recognized by the endogenous SLP65. To confirm that 
the N-BAR-SLP65 chimera was indeed localized similarly to WT SLP65, I compared the 
degrees of colocalization of WT and N-BAR-ΔN SLP65 with quinacrine. Both variants 
colocalized equally well with this marker, indicating that similar types of vesicles were 
targeted by the N-BAR-ΔN SLP65 fusion protein (Figure 4.17). 
 
 
Figure 4.17 N-BAR-ΔN SLP65 colocalizes with quinacrine-positive vesicles. 
DT40 slp65-/- cells reconstituted with WT or N-BAR-ΔN SLP65 were stained with quinacrine. Z-
stacks of images in the Citrine- and Cerulean- channel were taken and colocalization of SLP65 and 
quinacrine was analyzed by Image J. For quantification, the means ± SD of 10 Z-stacks (each 


























The data presented so far showed that anchoring SLP65 to small vesicles via the N-BAR 
domain of Amphiphysin suffices for signaling. It has been reported, however, that SLP65-
CIN85 interaction also contributes to the precise subcellular localization of SLP65. I 
therefore wondered whether the N-BAR-ΔN SLP65 chimera was still dependent on CIN85 
binding or if the curvature-sensing BAR domain could bypass the requirement for CIN85. 
Proline-rich regions of SLP65 act as CIN85-binding sites, and single point mutations of R 
to A at 2 of these proline-rich regions suffice to abolish CIN85 binding (Oellerich et al., 
2011). I introduced these inactivating mutations to the N-BAR chimeric protein, thereby 
generating a chimera termed N-BAR-ΔN SLP65 M23 (Figure 4.18 A). This chimeric 
protein with inactivated CIN85-binding sites had a strongly compromised Ca2+ mobilization 
profile and was not recruited to the plasma membrane after BCR-stimulation. Moreover, it 
was localized exclusively in the cytosol of resting cells, and not in the vesicular structures 
(Figure 4.18 B). Additionally, no vesicular localization of full-length SLP65 harboring the 
M23 mutations was observed (Engelke et al., 2014). This result indicated that the 
membrane-binding by the N terminus alone is insufficient for vesicular targeting of SLP65. 
Instead, CIN85 binding co-operates with the SLP65 N terminus for bringing SLP65 to its 
precise subcellular compartment. In addition, CIN85 binding could also amplify the 
signaling capability of vesicle-associated SLP65, since CIN85 is able to dimerize via its 
CC domain (Bremes, 2012)and unpublished data from the lab) and could therefore 






Figure 4.18 N-BAR-ΔN chimera is dependent on CIN85 binding. 
A) Schematic representation of the chimeric proteins harboring the N-BAR domain at the N 
terminus fused to either SLP65 ΔN WT or to SLP65 ΔN M23 (harboring the inactivating mutations 
R248,331A. B) DT40 slp65-/- cells were retrovirally transduced with the N-terminally Citrine-tagged 
constructs represented in (A) and Ca2+ flux was monitored by flow cytometry. The Ca2+ profiles of 
the cells with equal Citrine expression are shown. C) CLSM imaging analysis of the cells 
expressing Citrine-tagged N-BAR-ΔN and N-BAR-ΔN M23 chimeras. Images before and 3 min 
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4.2.4 The CC domain of CIN85 is a lipid-binding domain, which preferentially binds 
to phosphatidic acid 
My data indicated that CIN85 binding and the N terminus of SLP65 act in concert for 
proper membrane targeting of SLP65. Data accumulated by J. Kühn has shown that 
CIN85 mainly mediates its SLP65 targeting-related function via the CC domain 
(unpublished data). Interestingly, the CIN85 CC domain was also reported to have a lipid-
binding function, similarly to the N terminus of SLP65. The CC domain was shown to bind 
phosphatidic acid (PA), as detected by lipid-protein overlay PIP-strip assays (Zhang et al., 
2009). I aimed to confirm the binding of CIN85 to PA using the liposome floatation assays. 
SUVs containing 1, 5 or 10 % PA were prepared with the “detergent removal” method. 
The recombinant protein harbouring the CIN85 CC domain fused to SLP65 ΔN (CC-ΔN) 
was used in the floatation experiments. SLP65 ΔN was used as a control, in order to 
exclude unspecific binding to PA-containing liposomes. As shown in Figure 4.19, CC-ΔN 
associated with liposomes containing 5 and 10% PA (left panel), while ΔN was mostly 




Figure 4.19 CIN85 CC domain binds to PA-containing liposomes.  
SUVs, consisting of 75% PC, 25% PE (PC:PE only), or containing 1, 5 or 10% PA (added at the 
expense of PC) were incubated with recombinant His6-tagged CC-ΔN or ΔN SLP65 and a liposome 
floatation experiment was performed. Representative immunoblots, developed with an α-SLP65 
antibody, are shown.  
CC-ΔN ΔN












These data show that the CIN85 CC domain can bind PA in vitro. It is possible that this 
interaction targets CIN85 to vesicular membranes inside the cell. CIN85 could then recruit 
SLP65 to PA-positive vesicles, thereby enriching SLP65 at specific vesicular membranes. 
It is however not clear if the affinity of the CC domain for PA is sufficiently high to 
recognize this relatively low abundant lipid inside the cell. The functional role of CIN85-PA 
interaction, as well as further properties of the CIN85 CC domain was investigated by J. 
Kühn during his doctoral work.   
4.2.5 The SLP65 N terminus is disordered in solution, but binds to liposomes in a 
defined manner 
The data presented so far indicated that the SLP65 N terminus is a curvature sensing 
lipid-binding domain which targets SLP65 to vesicles. In order to better understand how it 
interacts with membranes, I and my collaborators in the group of Prof. Christian 
Griesinger aimed at elucidating the conformation and the secondary structure of the N 
terminus within the lipid bilayer. For this purpose, recombinant 15N-1H labeled protein 
encompassing the residues 5-50 of SLP65 was expressed in and purified from E.coli. The 
NMR spectrum of the isolated SLP65 N terminus was recorded and the residue 
assignment was performed. The low chemical shift dispersion of the backbone amides 
indicated disordered conformation of the N terminus in aqueous solution (Figure 4.20 A). 
This was in accordance with the fast water-amide proton exchange rates, indicating 
solvent exposure and confirming a lack of secondary structure (data not shown).  
Furthermore, I analyzed the secondary structure of the SLP65 N terminus with Circular 
Dichroism (CD) spectroscopy. CD is a useful tool to estimate protein secondary structure 
and folding properties, even though it doesn’t provide the residue-specific resolution 
obtained by NMR (Greenfield, 2006). As shown in Figure 4.20 B, the CD spectrum of 
SLP655-50 closely resembled that of a random coil, with a characteristic minimum of the 
CD curve around 200 nm. Therefore, it appeared that the SLP65 N terminus, similarly to 
the large central part of SLP65, lacked secondary structure in solution and had a 
conformation of an intrinsically disordered protein. This was inconsistent with the 
prediction by protein secondary structure prediction tools, which predict presence of an 
amphipathic α-helix in the SLP65 N terminus (prediction by Amphipaseek;(Sapay et al., 
2006). I hypothesized that binding to membranes could induce folding of the N terminus 
into an α-helical confirmation and therefore investigated the secondary structure of the 
isolated SLP65 N terminus in the presence of liposomes.  
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Figure 4.20 The N terminus of SLP65 is intrinsically disordered in solution. 
A) The 15N-1H HSQC spectrum of SLP655-50 at 25 °C in aqueous solution. B) The CD spectrum of 
SLP655-50 in aqueous solution. C) Reference CD spectra of representative proteins, (image taken 
from(Trivedi & Chaudhary, http://nptel.ac.in/courses/102103044/module2/lec9/2.html). SLP655-50 
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SLP655-50 was tested for binding to SUVs by means of liposome floatation assays. His-
tagged SLP655-50, harboring a C-terminal ZZ solubility-tag, was incubated with SUVs 
consisting of PC and PE and subjected to the liposome floatation assay. As shown in 
Figure 4.21 A, the isolated N terminus was found in the upper liposomal fractions, similarly 
to WT SLP65, indicating its binding to the liposomes. After confirming that SLP655-50 binds 
lipids, we proceeded with the structural investigations: the protein was incubated with 
increasing amounts of SUVs and its NMR and CD spectra were recorded.  
Figure 4.21 B shows the NMR spectra of SLP655-50 before and after incubation with SUVs. 
Upon addition of SUVs, attenuation of intensities of individual peaks on the HSQC 
spectrum was observed. Adding more concentrated liposome solutions resulted in greater 
intensity attenuations. The ratio of peak amplitudes after and before the addition of 
liposomes (A/A0) was plotted against the amino acid sequence of the protein (Figure 4.21 
C). The residues with the highest intensity attenuation (lowest A/A0) are the ones involved 
in binding to the liposomes or found in the vicinity of the liposome-binding sites.  
The NMR analysis has confirmed the interaction of SLP65 with lipids and identified the 
individual residues mediating the interaction. However, it was yet not clear whether SLP65 
adopts a different secondary structure when bound to the membrane. To further 
investigate the effect of lipid binding on SLP65 conformation, I recorded the CD spectrum 
of the N terminus in the presence of different amounts of SUVs. As can be seen in Figure 
4.22 A, addition of PC:PE SUVs did not have an effect on the CD spectrum. However, the 
CD spectrum of a protein is derived from the average absorbance of all molecules in the 
sample. Therefore, if the majority of molecules have one conformation and only a small 
percentage of molecules have a different conformation, the effect of the low-populated 
conformation might not be reflected in the CD curve. Given the low affinity of SLP65 for 
neutral SUVs, it is probable that only few SLP65 molecules are bound to the liposomes. 
However, even if they are undergoing a conformational change, this would not produce a 
detectable effect in the CD spectrum. In order to increase the liposome-bound population 
of SLP65, I recorded the CD spectrum of SLP655-50 in the presence of negatively charged 
(PS-containing) SUVs, for which the peptide has a higher affinity. However, as shown in 
Figure 4.22 B, even in the presence of negatively charged SUVs no change in the CD 
spectrum was observed, indicating that the random coil conformation of SLP65 persists 





Figure 4.21 SLP655-50 binds to SUVs in a defined manner. 
A) A liposome floatation experiment was done with WT SLP65 and SLP655-50. A representative 
immunoblot, developed with an α-His antibody, is shown. B) 15N-1H HSQC spectra of SLP65 before 
and after addition of 10.9 mM (total lipid concentration) liposomes. C) The ratio of peak intensities 
in HSQC of SLP655-50 before and after addition of liposomes (A/A0) was plotted against the amino 
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Figure 4.22 Lipid binding does not induce a structural change in the SLP65 N terminus. 
CD spectra of SLP655-50 alone or in the presence of SUVs consisting either of (A) PC:PE (75:25) or 
(B) PC:PE:PS (65:25:10) were recorded. The total lipid concentration of the liposomes was 0.5, 1 
or 2 mM. However, the spectra with 2 mM lipid had to be discarded due to a high absorbance and 
a low signal to noise ratio below 200 nm.  
 
The structural analysis of the isolated SLP65 N terminus demonstrated that it is 
intrinsically disordered in solution and when bound to vesicles. It still cannot be excluded 
that lipid binding induces folding of the N terminus of SLP65 under conditions other than 
those used in our investigations. The NMR and CD experiments were performed at a 
relatively low protein:lipid ratio, where complete binding of SLP65 to the liposomes might 
not have been achieved. Therefore the small structural changes may have escaped 
detection. Moreover, it is not clear whether the N terminus maintains the disordered 
conformation in the context of the full length protein. To answer this question, further NMR 






















































4.2.6 Individual hydrophobic residues in the N terminus are essential for SLP65 
function, but dispensable for lipid binding 
NMR analysis has identified the residues in the SLP65 N terminus mediating the 
interaction with lipids. These turned out to be hydrophobic residues, such as leucine, 
isoleucine, valine and methionine, as well as charged residues, such as lysine. Detailed 
mutational analysis of the positively charged amino acids in the SLP65 N terminus has 
already been performed by N. Hermann in our lab (Herrmann, 2009). She found that 
substituting individual lysine residues with alanine did not affect the signaling capabilities 
of SLP65. I proceeded with the genetic analysis of this region of SLP65 and mutated the 
hydrophobic residues into alanine or glycine. These amino acid substitutions were chosen 
because alanine is an aliphatic amino acid with a short side chain, making insertion into 
the membrane unlikely, while glycine has a low propensity to form an α-helix. The 
following mutants of SLP65 were generated and transduced into slp65-/- DT40 cells: 
M21A, M21G, V22A, V22G, I32G, M33A, M33G, I36A, L39A and L39G. The expression 
level of different variants was confirmed by a Western blot with an α-SLP65 antibody and 
was comparable (Figure 4.23 C). In order to assess the signaling capability of the single 
point mutants of SLP65, Ca2+ mobilization was used as a read out. As shown in Figure 
4.23 A, all mutants had compromised Ca2+ mobilization profiles. For simplicity, only 
alanine mutants are presented here. Substitution to glycine had a very similar effect for 
most of the residues.  
CLSM imaging analysis was performed in order to analyze the subcellular localization and 
plasma membrane recruitment of the SLP65 variants. As shown in Figure 4.23 B, all 
mutants had a different subcellular localization from WT SLP65 – the dot-like vesicular 
distribution was not present and diffuse cytosolic distribution was observed instead. 
Moreover, many of the mutants, especially M33A/G, I36A and L39A/G, showed nuclear 
localization in resting and stimulated cells. Finally, some of the mutants were tested for 
lipid binding via liposome floatation assays. Surprisingly, all of the mutants were able to 
bind neutral SUVs. The only single point mutation that abolished lipid binding was the L18 
to K substitution. Interestingly, substitution of L18 to A also did not affect SUVs binding. A 
possible explanation could be that the mutations to A or G, preserving the aliphatic nature 
of the region, do not interfere with lipid binding of SLP65, whereas a mutation to K results 





Figure 4.23 Individual hydrophobic residues in the SLP65 N terminus are important for 
correct subcellular localization and signaling, but are dispensable for lipid binding. 
A) DT40 slp65-/- cells were reconstituted with Citrine-tagged SLP65 variants harboring single point 
mutations in the N-terminal region. Ca2+ mobilization was monitored by flow cytometry. The Ca2+ 
flux profiles of cells with equal Citrine expression are shown. B) CLSM imaging analysis of the 
Citrine-tagged SLP65 mutants. Images before and 3 mins after stimulation with 2 μg/ml α-chicken 
IgM antibody are shown. C) CCLs, prepared from DT40 cells expressing SLP65 variants, were 
analyzed for SLP65 expression by immunoblotting. D) A liposome floatation experiment was 
performed with recombinant His6-tagged SLP65 variants and PC:PE liposomes. Representative 












































































Collectively, my data indicates that hydrophobic residues in the SLP65 N terminus are 
critical for SLP65 activation and membrane recruitment, but are dispensable for lipid 
binding. This implies that the N terminus uses another mechanism, in addition to lipid 
binding, for targeting SLP65 to membranes. This could involve, for example, binding to a 
membrane protein ligand. However, it is still possible that the mutations analyzed actually 
reduce the affinity of SLP65 for lipids. This suffices to interfere with membrane targeting in 
the cell, however, the small change in affinity cannot be detected with the floatation 
assays. 
4.2.7 The N terminus plays a differential role for SLP65 membrane targeting and 
Ca2+ signaling in different species and at different stages of B cell 
development 
The data presented until now was generated using the SLP65-deficient DT40 cell line. It is 
a chicken B cell lymphoma line readily undergoing homologous recombination, which 
facilitates the generation of knock out cell lines (Winding & Berchtold, 2001). The DT40 
cell line can be classified as a pre-B cell line, since its BCR is still undergoing gene 
conversion of the light chain (Buerstedde et al., 1990; Kim et al., 1990). Moreover, BCR 
cross-linking in DT40 cells leads to apoptosis, unlike in more mature B cell types, where it 
induces proliferation and differentiation. Due to the species- and developmental stage-
specific properties of DT40 cells, I aimed to confirm my data on the function of the SLP65 
N terminus in a mature human B cell line.    
I used the SLP65-deficient DG75 cell line, kindly provided by C. Hitzing, generated via the 
TALEN-mediated method. Two slp65-/- clones, # 7 and # 28, were reconstituted with 
SLP65 WT, ΔN, or some of the single point mutants. The Ca2+ release profiles upon 
stimulation with α-human IgM antibodies of transfected and untransfected cells were 
recorded. For simplicity, the measurements with only one knock out clone, clone #7, are 
shown here. Slp65-/- DG75 cells mobilized very little Ca2+ upon BCR-stimulation, even 
though the Ca2+ flux of the knock out cell line was still stronger than that of the slp65-/- 
DT40 cell line (Figure 4.24 A, red line). This could be due to the presence of alternative 
adaptor proteins, which substitute the function of SLP65 in DG75 cells. Reconstitution of 
the cells with WT SLP65 resulted in a full restoration of the Ca2+ mobilization profile. 
Expression of the SLP65 variant lacking the N-terminal region, SLP65 ΔN, led to strongly 
impaired Ca2+ mobilization. Surprisingly, the single point variant SLP65 L18K, had a 
robust, only marginally impaired Ca2+ response (Figure 4.24 A). This was inconsistent with 
the data obtained from DT40 cells, where this variant elicited a very weak Ca2+ response, 
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comparable to that of SLP65 ΔN. Even more surprisingly, the ability of SLP65 L18K to 
support Ca2+ mobilization did not correlate with its ability to translocate to the plasma 
membrane upon BCR stimulation. The CLSM imaging analysis showed that both SLP65 
ΔN and L18K were not recruited to the plasma membrane. On the other hand, membrane 
translocation of WT SLP65 was also weaker and more difficult to detect than in DT40 cells 
(Figure 4.24 B).  
Finally, the Ca2+ mobilization profiles of other single point mutants of SLP65 were normal 
and comparable to that of WT SLP65 (Figure 4.24 C). These data indicated that even 
though the N-terminal region is required for SLP65 function also in DG75 cells, the 
contribution of individual hydrophobic residues to SLP65 membrane translocation and 
signaling might be different in human B cells, as compared to the chicken DT40 B cell line. 
It is also possible that the requirement for the SLP65 N terminus is higher in the immature 
DT40 B cell line than in mature DG75 cells.  
In order to further investigate the functional role of the SLP65 N terminus for SLP65 
activation and Ca2+ signaling, I performed experiments with slp65-/- primary mouse B cells. 
It has already been reported that the N terminus of SLP65 is required for pre-BCR 
signaling in mouse B cells. Slp65-/- pre-B cells reconstituted with signaling-incompetent 
variants of SLP65 I25E and L18E were unable to down-regulate their pre-BCR expression 
and to differentiate toward κ light chain surface expression (Kohler et al., 2005). I 
wondered whether SLP65 also depends on its N terminus for signaling in mature mouse B 
cells. I therefore isolated primary naïve B cells from spleens of adult slp65-/- mice, 
stimulated them with LPS to induce proliferation, and reconstituted them with Citrine-
tagged SLP65 WT, ΔN or L18K. The improved protocol for transfection of mouse 
splenocytes, optimized by L. König, was used (Bremes, 2012; König, 2012). The 
transfection efficiency 2 days after infection was 1-5%, as shown in Figure 4.25 A. 
Transfection of slp65-/- cells with all three constructs restored otherwise negligible Ca2+ 
flux of the knock out cells, even though the splenocytes transfected with WT SLP65 had 
the strongest Ca2+ response (Figure 4.25 B). SLP65 ΔN and L18K had only mildly 
compromised Ca2+ mobilization profiles, indicating that mature mouse B cells are less 
dependent on the SLP65 N terminus than mouse pre-B cells or the immature B cell line 
DT40. Stimulation of the cells with less antibody (10 or 5 μg/ml) resulted in a slightly lower 
Ca2+ response, but the small difference between the Ca2+ curves of WT and ΔN or L18K 





Figure 4.24 The N terminus of SLP65 is required, but individual hydrophobic residues are 
dispensable for SLP65 function in DG75 cells. 
Slp65-/- DG75 cells, kindly provided by C. Hitzing, were retrovirally transduced with constructs 
encoding Citrine-tagged SLP65 WT, ΔN or the single point mutants L18K, I32G, M33A, I36A or 
L39A. A) and C) Ca2+ mobilization in the knock out cell line and reconstituted cells was monitored 
by flow cytometry. Ca2+ mobilization profiles of cells with equal Citrine expression are shown. B) 
CLSM imaging analysis of the Citrine-tagged SLP65 mutants. Images before and 3 min after 
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Figure 4.25 The N terminus of SLP65 is dispensable for Ca2+ signaling in mouse primary B 
cells. 
Splenocytes isolated from slp65-/- mice were stimulated with LPS and retrovirally transduced with 
constructs encoding N-terminally Citrine-tagged SLP65 WT, ΔN or L18K. A) The transfection 
efficiency is indicated with a gate on Citrine-positive cells. B) Ca2+ mobilization was analyzed in 
parental and transfected cells with flow cytometry. The Ca2+ mobilization profiles of cells with equal 
Citrine-expression are shown. C) CLSM imaging analysis of transfected cells before and 3 min 
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Finally, subcellular localization and plasma membrane recruitment of SLP65 was 
analyzed in transfected cells with CLSM. In resting cells, all SLP65 variants localized to 
the cytosol (Figure 4.25 B). No dot-like vesicular distribution could be observed. However, 
one should note that due to the low transfection efficiency only a small number of cells 
could be analyzed. In stimulated cells, the translocation of WT SLP65 to the plasma 
membrane, but not that of ΔN and L18K variants, was observed. This result was 
consistent with the data from DG75 cells, where in a similar manner, SLP65 recruitment 
but not Ca2+ mobilization was affected by the mutations or the deletion of the SLP65 N 
terminus. A possible explanation for this observation is a small number of SLP65 
molecules being required to be present at the plasma membrane to initiate Ca2+ 
mobilization. In this case, even though plasma membrane targeting of N-terminal SLP65 
variants is defective and incomplete, enough molecules of SLP65 make it to the plasma 
membrane to initiate the Ca2+ release. Therefore the differences in the Ca2+ mobilization 
profiles are small or not observed.   
In conclusion, data from the DG75 cell line and mouse primary B cells indicated that the 
requirement for the SLP65 N terminus is different depending on the species and the 
developmental stage. This can be explained by differential expression of binding partners 
and proteins participating in SLP65 transport in chicken, mouse and human, and at 
different stages of B cell development.  
4.2.8 The SLP65 N terminus depends on the remaining SLP65 sequence for full 
functionality 
The data presented until now has indicated that the SLP65 N terminus has a previously 
unrecognized ability to bind lipids, which might target it to vesicles in living cells. Liposome 
floatation and NMR data have also shown that the isolated N terminus, i.e. the residues 5-
50 of SLP65, can bind liposomes. I next asked the question whether the N terminus can 
function as an autonomous protein domain and confer membrane localization to other 
proteins.  
In order to investigate whether the N terminus could function independently of its original 
location in SLP65, I generated a construct where the N-terminal 50 amino acids were 
deleted and newly fused at the C terminus, i.e. downstream of the SLP65 SH2 domain. 
This fusion protein, named SLP65 ΔN-Nt (Figure 4.26 A), was expressed in slp65-/- DT40 
cells and its subcellular localization and the ability to support Ca2+ signaling were 
analyzed. As shown in Figure 4.26 B, the cells expressing the ΔN-Nt chimeric protein 
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mounted a slightly better Ca2+ response than cells expressing the truncated variant SLP65 
ΔN. However, the Ca2+ response of ΔN-Nt was still significantly lower than that of WT 
SLP65. Consistent with its Ca2+ mobilization profile, SLP65 ΔN-Nt localized predominantly 
to the cytosol and no plasma membrane recruitment could be observed (Figure 4.26 C). 
These results indicated that the SLP65 N terminus at least partially depends on the 
remaining SLP65 sequence for full functionality. It is however also possible, that in the 
ΔN-Nt chimera the newly placed N terminus is too close to the SH2 domain of SLP65 and 
interferes with its function. Since the SH2 domain is indispensable for BCR-targeting of 
SLP65, this could account for the low Ca2+ mobilization profile of this chimeric protein. 
Finally, I wanted to see if the SLP65 N terminus could confer membrane association to 
another protein. In the study by Koehler et al, the localization of the SLP65 N terminus-
GFP fusion protein was investigated in the mouse B lymphoma cell line K46. This fusion 
protein localized predominantly to the cytosol, however, photo-bleaching of the GFP in the 
cytosol revealed that some SLP65 Nt-GFP was associated with the plasma membrane 
(Kohler et al., 2005). I have fused the SLP65 N terminus to CIN85, a protein participating 
in the same signaling cascade and presumably targeted to similar kind of vesicles as 
SLP65. CIN85 uses its CC domain for membrane association, since the mutant variant of 
CIN85 lacking this domain (CIN85 ΔCC) is not recruited to the plasma membrane upon 
BCR ligation (Zhang et al., 2009; Bremes, 2012). I generated a chimeric construct where 
the CC domain of CIN85 was replaced by the N terminus of SLP65 (Figure 4.26 A). This 
chimera (ΔCC-Nt) was expressed in cin85-/- DG75 cells, generated and kindly provided by 
K. Schulz, and its subcellular localization and plasma membrane recruitment was 
monitored by CLSM. As shown in Figure 4.26 C, the CIN85-SLP65 chimeric protein ΔCC-
Nt was distributed in the cytosol of resting and stimulated cells, similarly to ΔCC CIN85, 
i.e. no plasma membrane translocation of this variant was observed. In contrast, WT 
CIN85 was readily recruited to the plasma membrane upon BCR stimulation. These data 
show that the SLP65 N terminus cannot provide membrane association to CIN85, 
implying that the N terminus is not an autonomous domain and cannot function 
independently of SLP65. An alternative explanation would be that the affinity of the SLP65 
N terminus for lipids is very low, thereby making membrane association hard to observe 





Figure 4.26 The N terminus cannot function independently of SLP65. 
A) Schematic representation of the chimeric constructs SLP65 ΔN-Nt and CIN85 ΔCC-Nt. B) DT40 
slp65-/- cells were reconstituted with SLP65 WT, ΔN or ΔN-Nt. Ca2+ flux was monitored by flow 
cytometry. The Ca2+ flux profiles of cells with equal Citrine expression are shown. C) Subcellular 
localization and plasma membrane recruitment of SLP65 ΔN-Nt was analyzed by CLSM. Images 
before and 3 min after stimulation with 2 µg/ml α-chicken IgM antibody are shown. D) DG75 cin85-/- 
cells were retrovirally transduced with Citrine-tagged CIN85 WT, ΔCC or ΔCC-Nt. Subcellular 
localization and plasma membrane recruitment of CIN85 WT, ΔCC and ΔCC-Nt was analyzed by 
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B cell activation depends on the assembly of signaling complexes at the plasma 
membrane, organized by the adaptor protein SLP65. However, the precise mechanism of 
the plasma membrane targeting of SLP65 was not clear. In my thesis, I focused on 
deciphering the contribution of the N-terminal region of SLP65 for this process. My 
colleagues and I found that the N terminus mediates association of SLP65 with 
membranes in resting B cells. We showed that the N terminus targets SLP65 to 
intracellular vesicles in vivo and provides it the ability to bind lipids in vitro. The vesicular 
association of SLP65 is required for efficient plasma membrane translocation, implying 
that vesicular transport may deliver SLP65 to the BCR. NMR analysis of the SLP65 N 
terminus, performed in collaboration with the group of Prof. Christian Griesinger, showed 
that it is intrinsically disordered in solution, but binds to liposomes in a defined manner. 
Further structural analysis also identified long disordered regions in the central part of 
SLP65.  
5.1 Intrinsic disorder in SLP65 and its implications for SLP65 function 
The gap in understanding the activation process of SLP65 was at least partially related to 
the lack of knowledge about its secondary and tertiary structure. Several attempts to 
crystallize full-length SLP65 were unsuccessful (unpublished data from the lab), even 
though the crystal structure of the isolated SH2 domain of mouse SLP65 has been 
reported (Sano et al., 2007). The difficulties in obtaining a crystal structure can be 
explained by the presence of large intrinsically disordered regions in SLP65, as revealed 
by our NMR analysis. This is, at least partially, in agreement with the prediction by the 
secondary structure prediction softwares, which also predict a lack of secondary structure 
in the central part of SLP65 preceding the SH2 domain (prediction by the I-TASSER 
server;(Zhang, 2008), but suggest a coiled-coil structure in the N-terminal region 
(prediction by COILS and Amphipaseek;(Lupas et al., 1991; Sapay et al., 2006).  
I investigated the functional role of the intrinsic disorder in the central part of SLP65 by 
rearranging the phosphotyrosine motifs for Btk and PLCγ2 binding or by substituting this 
region with a disordered protein sequence. My results indicate that a secondary structure 
is not necessary for the assembly of the Ca2+ initiation complex, but might be required for 
the membrane targeting of SLP65. The intrinsic disorder may facilitate the scaffolding 
function of SLP65 and enable the simultaneous binding of several proteins to one SLP65 
molecule. However, Btk and PLCγ2 seem to assemble on SLP65 in a spatially defined 
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manner since exchanging their binding sites rendered SLP65 unfunctional (see Figure 
4.6). This implies that some degree of structural order should exist also in SLP65, at least 
in the vicinity of the Btk- and PLCγ2-binding sites. It is not uncommon for IDPs to undergo 
a disorder-to-order transition upon binding their targets (for review, see(Dyson & Wright, 
2002). It is therefore possible that Btk and PLCγ2 binding promotes SLP65 to take a more 
ordered conformation. Studies of the SLP65 molecular structure in a complex with Btk and 
PLCγ2 could answer the ultimate question of whether there is an ordered conformation of 
SLP65 within the Ca2+ initiation complex. 
Intrinsically disordered proteins usually bind their targets with high specificity, but low 
affinity. This is an advantage for signaling proteins that switch between “on” and “off” 
states for the regulation of signaling cascades. A flexible protein, such as SLP65, can 
form a more extended interaction surface than a structured protein - the flexibility allows 
for a precise fit to the target and thereby a high specificity. At the same time, an IDP has a 
lower affinity for its targets than an ordered protein, because in the latter case a perfectly 
fitting “bound” conformation exists before the binding takes place (reviewed by(Zhou, 
2012). Intrinsic disorder in SLP65 could therefore be essential for specific, but reversible 
binding of Btk and PLCγ2, as well as other interaction partners.  
My results also indicate that the central part of SLP65 has a previously unrecognized 
membrane targeting function, in addition to its already known role in membrane anchoring 
via binding to CIN85. From the cytosolic distribution of the synthetic protein SLP65 GS 
(see Figure 4.3 C) it can be assumed that the middle part of SLP65 is also involved in 
vesicle binding. It might support the function of the SLP65 N terminus or CIN85 for vesicle 
targeting or contain a binding site for a vesicle-resident protein. One promising candidate 
is Unc119, a protein identified as part of the SLP65 interactome, and shown to participate 
in vesicular trafficking in neurons and T lymphocytes (Gorska et al., 2009; Oellerich et al., 
2011; Zhang et al., 2011). Other, yet unidentified, binding partners of SLP65 could also 
mediate this targeting. However, it is also possible that the GS linker has a dominant 
negative, i.e. inhibitory effect on one or more of the SLP65 domains important for 
membrane recruitment. This would explain the phenotype of the GS and CC-ΔN GS 
variants (Figure 4.3).  
The functional importance of the central part of SLP65 is consistent with the relatively high 
degree of evolutionary conservation in this region. Not only the proline-rich regions and 
the tyrosine motifs, but also some negatively charged amino acids are conserved between 
species. This indicates once again that a total absence of secondary structure is unlikely. 
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Disordered sequences are usually less conserved than ordered protein domains. Further 
functional analysis, e.g. by means of targeted mutagenesis, and structural investigation of 
the central part of SLP65 is needed to identify possible structural transitions.  
5.2 The role of the SLP65 N terminus in the membrane targeting of SLP65 
The N-terminal region of SLP65 is characterized by a high abundance of positively 
charged and hydrophobic amino acids. This region is remarkably conserved between 
species, with more than 90% sequence identity at the protein level. The profoundly 
conserved nature of the SLP65 N terminus is indicative of its structural and/or functional 
importance. 
Indeed, as it was first demonstrated by(Kohler et al., in 2005,)the N terminus is essential 
for the function and membrane targeting of SLP65. The studies by my colleagues and me 
have confirmed that the N terminus is essential for the membrane association of SLP65, 
but our investigations point to a different molecular mechanism than that originally 
proposed by Koehler et al. A substitution of the residue I25, central to the proposed motif, 
with other aliphatic amino acids did not interfere with SLP65 function; excluding a 
functional leucine zipper (see Figure 4.9). Moreover, substitutions of those hydrophobic 
residues not corresponding to the heptad repeat of the leucine zipper, such as M21, V22, 
M33 and I36 to A and G, resulted in a strongly diminished Ca2+ flux and defective plasma 
membrane recruitment of SLP65 in DT40 cells (see Figure 4.23). This indicates a general 
requirement for the hydrophobic environment in the SLP65 N terminus.  
My results point to a function of the SLP65 N terminus in membrane association via direct 
lipid binding. It was previously found in our group that the N terminus of SLP65 can bind to 
PIP-spotted membranes (PIP strips). It was hypothesized that this part of SLP65 
constitutes a PIP-binding motif, which interacts with negatively charged lipids via 
electrostatic interactions (Herrmann, 2009). To confirm this finding, I used liposome 
floatation assays. In this method, PIPs are incorporated into a lipid bilayer, which provides 
a more “native” binding interface. I found that the SLP65 N terminus binds neutral 
liposomes independent of PIPs. Exchange of L18 to K abolished this interaction (see 
Figure 4.13 C), indicating the importance of hydrophobic residues in mediating lipid 
binding. This has been further confirmed by NMR analysis of the isolated N terminus 
(SLP655-50) in the presence of neutral liposomes. This analysis has identified the residues 
important for the liposome association – among them L18 (see Figure 4.21 C).  
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Together with my colleagues, Dr. M. Engelke and J. Kühn, we found that the N terminus 
confers membrane association to SLP65 already in resting DT40 cells, prior to any BCR 
stimulation. Constitutive association of the N terminus with membranes was already 
reported by Kohler et al.. However, they reported that SLP65 associates with the plasma 
membrane, and we, in contrast, argue that the vesicular membranes are targeted by 
SLP65 in resting cells. Detailed microscopic analysis revealed that the association of 
SLP65 with vesicles is reversible, as evident from the high fluorescence recovery rate 
upon photobleaching of vesicle-resident Citrine-tagged SLP65 (Figure 4.11). The cytosolic 
pool of SLP65 is also larger than the vesicular pool, as can be observed from fractionation 
studies and microscopic analysis. These observations indicate that the vesicle-SLP65 
association in resting cells is weak. This is consistent with the results of the liposome 
floatation experiments, which show that the affinity of the N terminus for lipids is not very 
high, at least when neutral lipid species are concerned. The intrinsic disorder and the lack 
of structural transition in the N terminus upon lipid binding further support the hypothesis 
that the SLP65-vesicle association is mediated by weak hydrophobic interactions.   
However, even this weak association seems to be critical for signaling, since the 
inactivation of the N terminus by mutations that shift the equilibrium towards the cytosolic 
fraction results in a signaling-incompetent SLP65, which cannot translocate to the plasma 
membrane and initiate the release of intracellular Ca2+ (see Figure 4.9 and 4.23). The 
vesicle residence of SLP65 in resting cells therefore appears to help the protein to get to 
the plasma membrane upon BCR stimulation. The easiest explanation for this observation 
is the use of vesicular transport by SLP65. Indeed, interference with vesicular trafficking 
by means of primaquine, a substance that inhibits budding of vesicles from donor 
membranes (Hiebsch et al., 1991), led to the inhibition of BCR signaling in DT40 cells 
(Engelke et al., 2014). Our studies therefore point towards a mechanism where the N 
terminus mediates association of SLP65 with vesicles in resting cells, which are 
transported to the plasma membrane and deliver SLP65 to the BCR upon antigen binding 





Figure 5.1 The model of SLP65 translocation to the plasma membrane on intracellular 
vesicles. 
The N terminus mediates the association of SLP65 with exosome-like vesicles in resting B cells. 
The vesicles carry the SNARE protein Vamp7 and are positive for ATP (detectable by quinacrine-
staining). Vesicular transport delivers SLP65 to the BCR upon activation. 
 
The vesicular route might not be the only mechanism for the SLP65 membrane 
translocation in B cells. Actually, my results indicate that in certain cases SLP65 can be 
recruited to the plasma membrane in an N terminus-independent manner. We 
investigated the vesicular residence of SLP65 in an immature B cell line DT40. Analysis of 
the subcellular localization of SLP65 in a mature human DG75 B cell line showed that the 
intracytoplasmic dot-like distribution of SLP65 is discernable, but not as prominent as in 
DT40 cells. Colocalization experiments with quinacrine have indicated that these 
intracellular speckles indeed represent the vesicular population of SLP65 (data not 
shown). However, the phenotype of the N terminus inactivation via deletion or amino acid 
exchanges was not as strong in DG75 cells as in DT40 cells. All single point substitution 
variants of SLP65 mounted an only slightly diminished Ca2+ response upon BCR 
stimulation even though the plasma membrane recruitment of SLP65 was compromised 
(see Figure 4.24). Similarly, slp65-/- mouse primary cells reconstituted with the ΔN and 
L18K variants of SLP65 mounted almost normal Ca2+ responses (see Figure 4.25). From 











developmental stages and the mechanism of SLP65 translocation via the vesicular route 
is more important for immature than for mature B cells. This is consistent with the finding 
by Koehler et al, who showed that the N terminus of SLP65 is essential for the pre-BCR 
signaling and for the developmental transition from the pre-B cell to the immature B cell 
stage (Kohler et al., 2005). The minor dependence of mature B cell types on the SLP65 N 
terminus implies that an alternative pathway regulates the membrane targeting of SLP65. 
It is possible that a regulator, expressed in a developmental stage-specific manner, 
inhibits the vesicular pathway or enhances alternative pathways of SLP65 recruitment to 
the plasma membrane in mature B cells. This regulator could be a direct SLP65 
interaction partner, or e.g. an enzyme modifying the lipid composition of the vesicles, 
making the attachment of SLP65 less/more likely. However, it is also possible that the 
differences in the requirement for the SLP65 N terminus are species-specific. In chicken, 
mouse and human there could be alternative molecules expressed which regulate the 
SLP65 membrane targeting.  
5.3 The proposed mechanism used by the SLP65 N terminus for membrane 
anchoring 
In this thesis I have identified a previously unknown interaction of the SLP65 N terminus 
with lipids. I showed that SLP65 associates with neutral liposomes independent of lipid 
composition, but has a higher affinity for negatively charged vesicles. Lipid binding by the 
N terminus is further specified by a much higher affinity for small vs. large vesicles, 
indicating SLP65 can recognize membrane curvature. This was further corroborated in 
vivo by the functional substitution of the N terminus with a curvature-sensitive N-BAR 
domain of Amphyphisin. My data indicates that the N terminus targets SLP65 to small 
negatively charged vesicles by virtue of reversible association with lipids. The involvement 
of hydrophobic residues for this interaction, as verified by our NMR analysis, suggests 
insertion of hydrophobic side chains into the lipid bilayer. However, the contribution of 
positively charged residues is also likely, since the N terminus bound stronger to 
negatively charged liposomes.  
Unlike many peripheral membrane proteins, which possess lipid-binding domains able to 
recognize certain phospholipid species, SLP65 doesn’t appear to have such a specific 
lipid-binding pocket and rather adheres to all negatively charged membranes. This 
electrostatic interaction with the membranes is therefore not very specific. Curvature 
recognition might contribute more to specificity, since SLP65 preferentially binds to the 
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liposomes with a radius of 20 nm, rather than to the liposomes with a radius of 60 nm (see 
Figure 4.15). Two mechanisms of curvature sensing used by other proteins have been 
described. One is the recognition of the geometric shape of the membrane, as is 
exemplary of BAR domains, which have a crescent-shaped fold that binds to membranes 
of certain curvature. The other mechanism is the recognition of lipid-packing defects, as is 
typical of ALPS motifs, which are intrinsically disordered sequences that form amphipathic 
α-helices on the membrane and insert the hydrophobic side chains between the loosely 
spaced lipids (for review, see(Antonny, 2011). The N terminus of SLP65 is more likely to 
use the latter mechanism, given its relatively small size, disordered nature in solution, and 
the predicted propensity to form an amphipathic α-helix (prediction by 
AmphipaSeek;(Sapay et al., 2006). However, no structural transition in the isolated N 
terminus was observed upon binding to SUVs (see Figure 4.21 and 4.22). Nevertheless, 
even in a disordered conformation curvature recognition could be mediated by the 
insertion of the hydrophobic side chains into the lipid bilayer. This is easier in a small 
vesicle, where the lipids are further apart than in a large vesicle with a more flat surface 
and closely packed lipids (Figure 5.2). The curvature of intracellular membranes is 
affected by their lipid composition. The presence of lipids with a small head group area, 
such as PE or DAG, has been shown to induce positive curvature by creating lipid packing 
defects (Vamparys et al., 2013). SLP65 could therefore have a preference for membranes 
enriched in such conical phospholipids. 
 
 
Figure 5.2 The proposed mechanism of curvature recognition by SLP65. 
SLP65 senses membrane curvature by detecting lipid-packing defects and inserting hydrophobic 
side chains between the loosely spaced lipids, thereby penetrating the lipid bilayer. In SUVs lipid 
heads are spaced further apart, facilitating the binding of the SLP65 N terminus. 
SUVs
R = 20 nm
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My data indicates that lipid binding might not be the only mechanism used by the SLP65 
N terminus for membrane targeting. Single amino acid substitutions in the N terminus did 
not abolish lipid binding, even though they compromised the plasma membrane 
recruitment of SLP65 (see Figure 4.23 D). The most plausible explanation is membrane 
anchoring by an alternative mechanism, such as via binding to a vesicle-resident protein, 
oligomerization, or lipid modification which promotes insertion of the N terminus into the 
membrane. Existence of a protein ligand for the SLP65 N terminus cannot be excluded, 
but the interaction partners which were described, such as BNAS2 (Imamura et al., 2004) 
or CaM (Herrmann, 2009), appear to be irrelevant for the membrane translocation 
process. Oligomerization of SLP65 via the N terminus has been proposed, but no 
experimental evidence for this hypothesis could be obtained (Engelke et al., 2014)and 
unpublished data from the lab).  
It is, however, also possible that the individual amino acid exchanges reduced the lipid-
binding affinity of the SLP65 N terminus. This change could not be detected by the “semi-
quantitative” method of liposome floatation, but was sufficient to compromise membrane 
targeting in the cell. The investigation of the lipid-binding affinity of SLP65 with quantitative 
methods, such as ITC (isothermal titration calorimetry), FCS (fluorescence correlation 
spectroscopy) or NMR, will be useful to confirm the relevance of the SLP65-lipid 
interaction in living cells and might explain the phenotypes of the single point variants.  
There might be yet another explanation as to why some of the single point mutants of 
SLP65 failed to initiate BCR signaling. One should note that exchanges of some amino 
acids, especially residues I36 and L39 for A, G or K, resulted in a strong nuclear 
localization of SLP65, as visualized by CLSM (see Figure 4.23 B). This mis-localization 
could account for the insufficiency of SLP65 in the cytoplasm and at the vesicles, which I 
term the “dilution effect”. This would explain the inability of these variants to reach the 
plasma membrane upon BCR ligation. This observation further supports the general 
notion that the N terminus regulates subcellular localization of SLP65 in resting cells. But 
why is SLP65 imported into the nucleus? Nuclear localization signals (NLSs) are short 
stretches of basic amino acids, which are recognized and bound by importins, proteins 
mediating the nuclear import (Marfori et al., 2011). The NLS sequences are diverse and 
not very specific. The subcellular localization of proteins is further specified by the 
presence (or absence) of nuclear export signals (NES), which are bound by exportins and 
direct proteins out of the nucleus. Abundance of lysine and arginine residues in SLP65 
could lead to the nuclear import “by default”, i.e. due to the unspecific binding of the 
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positively charged residues by importins. However, since SLP65 is not found in the 
nucleus under normal conditions, it needs a NES site to be exported out of the nucleus. 
The classical leucine-rich NES consensus sequence, recognized by the exportin CRM1, is 
φ-X(2,3)-φ-X(2,3)-φ-X-φ, where φ is L, V, I, M or F, and X(2,3) represents any two or three 
amino acids (Dong et al., 2009). The sequence 32-IMNKIKKLKV-39 in SLP65 fits this 
pattern and could function as a NES site. Inactivation of the NES motif by substitution of 
the critical residues I32, I36 or L39 would prevent recognition by CRM1 and nuclear 
export, which explains the nuclear localization of the respective single point mutants.  
I conclude that the N terminus targets SLP65 to vesicles by virtue of direct lipid binding. 
However, lipid binding alone might be insufficient for stable vesicle association. It is likely 
that another mechanism exists, such as dimerization or interaction with a transmembrane 
protein, which further stabilizes this interaction. 
5.4 The N terminus cooperates with CIN85 for the efficient membrane 
targeting of SLP65  
Peripheral membrane proteins, which adhere to membrane surfaces from the cytosol, are 
surrounded by tens of millimolar of lipids. This high value implies that a high affinity is not 
needed for membrane association; instead the specificity of binding is important, i.e. the 
protein must be able to distinguish one membrane compartment from another (Bigay & 
Antonny, 2012). In case of SLP65, the specificity is moderate: curved and negatively 
charged membranes are targeted by the lipid-binding motif in the N terminus. In that case, 
how does it tether SLP65 to a particular vesicle species inside the cell? 
It is possible that additional specificity is provided by other domains or interaction partners 
of SLP65. I propose a model, where first, the N terminus concentrates SLP65 at all 
negatively charged curved membranes. Then, binding of SLP65 to a vesicle-resident 
ligand enriches SLP65 at a particular type of vesicle (see Figure 5.3). This ligand could be 
CIN85 or another binding partner of SLP65. I and my colleagues showed that the CIN85 
binding is indeed required for the vesicular localization of SLP65. The CIN85 binding-
deficient variant, SLP65 M23, is distributed in the cytosol of resting DT40 cells similarly to 
the SLP65 ΔN (Engelke et al., 2014). This is also valid for the N-BAR-SLP65 chimeric 
protein with inactivated CIN85-binding sites, which is also not localized at intracellular 
vesicles and cannot activate Ca2+ mobilization (see Figure 4.18). Hence, targeting SLP65 
to small negatively charged vesicles is insufficient for signaling and needs to be supported 
by CIN85 binding.  
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It was shown by J. Kühn that the CC domain of CIN85 can substitute the SLP65 N 
terminus for membrane targeting. The CC domain may anchor CIN85 to membranes via 
its interaction with phosphatidic acid. I confirmed this interaction with liposome floatation 
assays. However, interfering with the PA metabolism by inhibition of the PA-producing 
enzymes PLD1 and PLD2 did not affect the association of CIN85 with membranes (data 
not shown). Moreover, the signaling-incompetent mutant variant of the CC domain could 
still associate with the PA-containing liposomes, indicating that PA binding is not the 
essential function of the CC domain (unpublished data, in collaboration with J. Kühn). The 
CC domain of CIN85 is also implicated in protein hetero- and homo-oligomerization 
(Gaidos et al., 2007). This could bring several SLP65 molecules together and amplify 
BCR signaling.  Therefore, CIN85 binding may both navigate and amplify the signaling by 
SLP65. The exact contribution of CIN85 to SLP65 activation was investigated by J. Kühn 
in his doctoral work.  
 
 
Figure 5.3 The model of vesicle targeting by the SLP65 N terminus. 
The N terminus adheres to negatively charged curved membranes. The specificity is provided by 
the binding to CIN85 and/or to a hypothetical vesicle-resident protein XYZ. The vesicles are 
transported to the plasma membrane upon BCR stimulation and deliver the associated signaling 






















5.5 The vesicular route for the plasma membrane targeting of signaling 
proteins in lymphocytes 
Our results indicated that the association of SLP65 with vesicles is essential for BCR 
signaling. The advantage of this mechanism could be a more efficient signaling initiation, 
since instead of being directly recruited from the cytosol to the plasma membrane, 
signaling proteins can be recruited as part of the pre-assembled signaling complexes. 
This is especially useful for adaptor proteins, which, unlike enzymes, cannot activate 
several targets at a time and therefore rely on direct or indirect oligomerization.  
The vesicle-mediated recruitment of signaling proteins to the plasma membrane could be 
a general mechanism not specific for B cells, but also used by other receptor systems. 
Indeed, there is emerging evidence that similar mechanisms operate in T lymphocytes. 
Signaling downstream of the TCR depends on the integral plasma membrane protein Lat. 
Recently this adaptor protein was also detected on intracellular vesicles (Bonello et al., 
2004). In a study using immobilized T cell-APC conjugates, Lat-containing vesicles were 
found to move rapidly between the surface microclusters containing adaptor protein 
SLP76 at the immunological synapse. The motility of these vesicles decreased and Lat 
phosphorylation took place in the proximity of the SLP76-containing microclusters 
(Purbhoo et al., 2010). Other TCR signaling proteins, such as Lck and TCRζ, were also 
described to reside in the exocytotic vesicular compartments, yet distinct from those 
containing Lat. The adaptor protein SLP76 was not detected at intracellular vesicles. 
However, its phosphorylation and distribution at the immunological synapse was affected 
by the inhibition of vesicular traffic and fusion (Soares et al., 2013). The mechanisms of 
vesicular trafficking in T lymphocytes are just beginning to be unravelled. Recently, the 
SNARE protein Vamp7 was discovered to be required for the recruitment of Lat-containing 
vesicles to the TCR and for the subsequent activation of T cells (Larghi et al., 2013).  
We also observed colocalization of SLP65 with Vamp7 in DT40 B cells (Figure 4.10 
and(Engelke et al., 2014). B and T lymphocytes may therefore use similar mechanisms for 
the transport of vesicle-associated signalling proteins to the cell surface. In support of this 
hypothesis, modification of SLP76 by the addition of the SLP65 N terminus and the 
CIN85-binding sites enabled it to fully reconstitute Ca2+ signaling in slp65-/- DT40 cells 
(unpublished data from Dr. M. Engelke). It is therefore plausible to assume that SLP65 
and SLP76 both can engage in the vesicular route of membrane targeting, although they 
use different anchors to attach themselves to the vesicles.  
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No significant colocalization of SLP65 was observed with any of the Golgi and endosomal 
markers tested. In fact, SLP65 was found to colocalize with only two vesicular markers – 
Vamp7 and quinacrine (Engelke et al., 2014). Vamp7, also known as TI-VAMP, is a 
vesicle (v-) SNARE protein, which was linked to both endocytic and exocytic pathways, 
depending on the cell type (Martinez-Arca et al., 2000; Oishi et al., 2006; Krzewski et al., 
2011). We analysed the subcellular distribution of Vamp7 in DT40 cells with cryo-electron 
microscopy in collaboration with the research group of Prof. H. Stark and found that 
Vamp7 marks multiple vesicle types of a wide size range in DT40 B cells (data not 
shown). This observation indicated that Vamp7 is not a very specific marker for the 
SLP65-containing vesicles and is consistent with an only moderate degree of 
colocalization between the two proteins (Mander’s coefficient ~0.2, i.e. 20% 
colocalization). Another exosomal vesicular marker that characterised SLP65-positive 
vesicles was the dye quinacrine, which stains intracellular ATP. ATP has been shown to 
act as a paracrine/autocrine signaling molecule in several cell types (for review, 
see(Corriden & Insel, 2010). In B lymphocytes, ATP is stored in intracellular secretory 
granules and released upon ligation of the BCR or the Toll-like receptor (TLR). 
Extracellular ATP is then hydrolysed by enzymes in the plasma membrane into 
adenosine, which induces class switch recombination in B cells (Schena et al., 2013). It is 
unlikely that the plasma membrane targeting of SLP65 is coupled to this process, since 
we used the immature DT40 B cell line for the colocalization analysis, which does not 
undergo class-switch recombination. However, it is possible that intracellular ATP, 
transported to the plasma membrane in SLP65-containing vesicles, likewise plays a 
signalling role for another B cell response, such as e.g. apoptosis in DT40 cells. 
Interestingly, the release of Lat- and TCRζ- containing vesicles in T lymphocytes, as well 
as the fusion of the ATP-carrying secretory vesicles in B lymphocytes, was regulated by 
calcium (Schena et al., 2013; Soares et al., 2013). It is possible that Ca2+, liberated upon 
BCR activation, also further stimulates the release of the SLP65-containing vesicles in a 
positive feedback-regulatory loop. 
Even though the origin of SLP65-positive vesicles is still elusive, we have a hint that they 
originate from the trans-Golgi network (TGN). Fusing the PH domain of the protein 
OSBP1, which binds phosphatidylinositol-4-phosphate, a lipid species specifically located 
on TGN, to ΔN SLP65 was sufficient to bring it to the plasma membrane and to initiate 
Ca2+ mobilization upon BCR stimulation (Engelke et al., 2014). This indicates that 
targeting SLP65 to the Golgi network suffices for signaling. Moreover, this experiment 
once again shows that the N terminus of SLP65 can be substituted by a lipid-binding 
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domain. Interestingly, the loss of CIN85 binding by means of amino acid substitutions in 
the proline-rich regions of SLP65 resulted in the colocalization of the respective M23 
mutant with a TGN marker; indicating that in the absence of CIN85 binding SLP65 is 
“trapped” in the Golgi network (Engelke et al., 2014). These data further support the 
notion that CIN85 binding further specifies vesicular targeting of SLP65, which is initiated 
by the N terminus. Nevertheless, colocalization analysis with more vesicular markers is 
needed to characterize and understand the origin of the SLP65-containing vesicles. 
Moreover, it would be interesting to analyse the subcellular distribution of other BCR-
signaling proteins, such as Lyn, Syk, Btk, BCR subunits, etc., to investigate their potential 
involvement in the vesicular route of plasma membrane targeting.  
The mechanisms of vesicular transport in lymphocytes are not clear. It is probable that 
cytoskeleton reorganization plays a major role for this process. BCR signaling induces 
cytoskeleton depolymerisation and re-polymerization (Hao & August, 2005). Moreover, it 
was shown that alteration of the actin cytoskeleton in B cells by using pharmacological 
agents that disrupt the actin network, such as Latrunculin A and Cytochalasin D, is 
sufficient to trigger BCR signaling (Treanor et al., 2010). CLSM imaging analysis has also 
shown that treatment of DT40 cells with Latrunculin B results in a rapid translocation of 
SLP65 to the plasma membrane (unpublished data from the lab). It is therefore possible 
that the disruption of the actin cytoskeleton induces the release of intracellular vesicles 
containing SLP65 and maybe other signaling proteins. In support of this idea, constitutive 
interaction partners of SLP65, CIN85 and CD2AP, have a link to the actin cytoskeleton. 
CIN85 and CD2AP interact with CapZ isoforms, proteins involved in capping the barbed 
end of actin filaments and preventing the actin from depolymerisation (Hutchings et al., 
2003). The functional role of these interactions is not clear. CD2AP additionally has 
several actin-binding sites (Kirsch et al., 1999; Tibaldi & Reinherz, 2003). Further 
investigations are therefore needed to understand the contribution of the cytoskeleton re-
organization to the vesicular transport and BCR signaling.  
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5.6 Conclusions and perspectives 
Together with my colleagues, I showed that the adaptor protein SLP65, which was 
previously considered to be a purely cytosolic protein, resides at vesicles in resting B cells 
and that this vesicle association is important for BCR signalling. I identified the vesicle-
anchoring device as the N terminus of SLP65, which is a direct lipid-binding module. Our 
findings point to a mechanism where the adaptors SLP65 and CIN85 are delivered to the 
plasma membrane via vesicular transport upon BCR ligation. Such a mechanism 
circumvents recruitment of individual cytosolic proteins from the cytosol and is therefore 
advantageous for efficient signaling initiation.  
The origin and protein composition of the herein identified signaling vesicles remains to be 
elucidated. Advanced microscopy techniques, such as STED (Stimulated emission 
depletion) and/or TIRF microscopy, should be applied to visualize the direct movement of 
the vesicles to the plasma membrane upon BCR stimulation. It would be also interesting 
to investigate whether the SLP65-positive vesicles fuse with the plasma membrane, as 
this appears not to be the case for the Vamp7- and Lat-positive vesicles in T lymphocytes 
(Larghi et al., 2013). In order to characterize the protein composition of the SLP65/CIN85-
containing vesicles further, they should be separated from other organelles in the cells. 
This has not been possible so far due to the absence of specific protein markers, which 
are stably associated with the vesicles. Colocalization analysis with more vesicular 
markers is therefore necessary to identify further vesicle-resident proteins. Once such 
markers are identified, biochemical approaches such as protein immunoprecipitation or 
affinity purification may be used to isolate the specific vesicular species. Alternatively, 
fluorescence-activated vesicle sorting may be applied for this purpose. Such flow 
cytometry-based techniques have been used to isolate exocytotic vesicles in other cell 
types (Cao et al., 2008). The isolated vesicles should then be subjected to mass 
spectrometry techniques to identify their protein constituents. It would also be interesting 
to investigate the lipid composition of the SLP65-positive vesicles with TLC (Thin Layer 
Chromatography) or similar techniques.  
The investigation of the SLP65 structure by NMR spectroscopy has shown that SLP65 is 
intrinsically disordered in the N-terminal and central regions. Structural studies of the full-
length protein, instead of truncated variants, are necessary to verify the present data and 
to explore potential intramolecular interactions within SLP65. To detect possible structural 
transitions upon activation, it would be useful to investigate the secondary structure of 
SLP65 in the presence of its inducible interaction partners. For this purpose, SLP65 
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should be phosphorylated in vitro by Syk kinase and the NMR spectra in the presence of 
Btk and/or PLCγ2 SH2 domains should be recorded. Finally, structural investigations of 
the N-terminal single amino acid substitution variants of SLP65 may be useful to 
understand their loss-of-function phenotype, despite an unaffected ability to bind lipids. To 
fully comprehend the plasma membrane recruitment process of SLP65 it is also crucial to 
study the function of the central proline-rich region of the protein. Further mutational 
analysis of this part should be performed and respective deletion and single point mutants 
should be reconstituted into SLP65-deficient cell lines in order to narrow down the critical 
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DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
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HSQC Heteronuclear single quantum coherence spectrum 
Hsv2 Homologous with swollen vacuole phenotype 2 
IDP Intrinsically disordered protein 
Ig Immunoglobulin 
IκB Inhibitor of NF-κB 
IKK IκB kinase complex 
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IP3R IP3 receptor 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ITAM Immunoreceptor tyrosine-based activation motif 
ITC Isothermal titration calorimetry 
Itk IL2-inducible T cell kinase 
JNK c-JUN NH2-terminal kinase 
LAT Linker for activation of T cells 
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Lck Lymphocyte-specific protein tyrosine kinase 
LPS Lipopolysaccharide 
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Lyn Lck/Yes-related tyrosine kinase 
MACS Magnetic-activated cell sorting 
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min Minute(s) 
MLV Multilamellar vesicle 
Nck Non-catalytic region of tyrosine kinase 
Neo Neomycine 
NES Nuclear export signal 
NFAT Nuclear factor of activated T cells 
NF-κB Nuclear factor for kappa gene in B lymphocytes 
NLS Nuclear localization signal 
NMR Nuclear Magnetic Resonance 
N-terminal Amino-terminal 
NTAL Non-T cell activation linker 
OD Optical density 
OG Oregon Green 
OSBP1 Oxysterol-binding protein 1 
PA Phosphatidic acid 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PIK Phosphatidyl inositol kinase 




PKCβ Protein kinase C 
PLC-γ2 Phospholipase C-γ2 
PLD Phospholipase D 
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PRR Proline-rich region 
Pre- Precursor 
PS Phosphatidylserine 
PTK Protein tyrosine kinase 
pY Phosphotyrosine 
Raf Rat fibrosarcoma 
Ras Rat sarcoma 
RasGRP3 Ras guanyl-releasing protein 3 
RNA Ribonucleic acid 
ROI Region of interest 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
sec Second 
SH2 Src-homology 2 
SH3 Src-homology 3 
SHP-1 SH2 domain-containing protein tyrosine phosphatase 1 
SLP-65 SH2 domain containing leukocyte adaptor protein of 65 kDa 
SLP-76 SH2 domain containing leukocyte adaptor protein of 76 kDa 
SNARE Soluble N-ethylmaleimide-sensitive factor 
SOC Store-operated Ca2+ channel 
Sos Son of sevenless 
STED Stimulated emission depletion microscopy 
STIM1 Stromal interaction molecule 1 
SUV Small unilamellar vesicle 
Syk Spleen tyrosine kinase 
TAE Tris acetate EDTA buffer 
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TAK1 Transforming growth factor beta-activated kinase 1 
TALEN Transcription activator-like effector nuclease 
TBS Tris buffered saline 
TCR T cell antigen receptor 
TEMED N,N,N’,N’-tetramethylethylene-diamine 
TGN Trans-Golgi network 
TIRF Total internal reflection microscopy 
TLC Thin layer chromatography 






VL Light chain variable domain 
Vav GDP/GTP exchange factor for Rho family GTPases 
VH Heavy chain variable domain 
VSV-G Vesicular stomatitis virus glycoprotein 
v/v Volume/volume 
WT Wild type 
w/v Weight/volume 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
ZAP-70 ζ-associated protein of 70 kDa 
 
7.4 Amino acids 
Amino acid 3 letter code Single letter code 
Alanine Ala A 
Aspargine Asn N 
Aspartic acid Asp D 
Arginine Arg R 
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Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
7.5 Deoxyribonucleotides 
Deoxyribonucleotide Symbol 
Deoxyadenosine monophosphate A 
Deoxycytidine monophosphate C 
Deoxyguanine monophosphate G 
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